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Circadian rhythms in mammals, such as metabolism, hormone release, and the 
sleep/wake cycle, are orchestrated by the suprachiasmatic nucleus (SCN) located in the 
hypothalamus. Mass spectrometry peptidomics of the SCN identified the small peptide 
cerebellin-short (SGSAKBSAIRSTN) consisting of 15 amino acids, which is released 
from the SCN in circadian fashion. Cerebellin-short is the C-terminus truncated form 
of the 16 amino acid cerebellin peptide highly enriched in the cerebellum. The 
distribution of cerebellin-short in the SCN and the functional implications of its 
circadian release, however, are unknown.  Here we showed that the precursor of 
cerebellin-short, Cbln1, is expressed in the SCN with daily oscillations in mRNA 
level. The level of Cbln1 process intermediate also oscillates around the day. 
Immunofluorescence revealed that a portion of both AVP- and VIP- positive cells in 
the SCN are also positive for cerebellin-short. Cbln1 on the other hand localized 
immediately dorsal to the SCN along the 3rd ventricle. Cbln1 also showed strong 
localization to the paraventricular nucleus (PVN), the supraoptic nucleus (SON) and 
the median eminence. No Cbln1 or process intermediate were observed in GFAP-
positive astrocytes. Crude synaptosome fractionations of the SCN revealed that the 
processing intermediate, but not Cbln1, is enriched at the synapse. Exogenous 
application of cerebellin-short at midday and early night phase advance the 
spontaneous firing rhythm of SCN neurons. These results suggest that Cbln1 is 
actively processed into cerebellin-short at the synapses throughout the SCN, and is 
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CHAPTER ONE: INTRODUCTION 
1.1 CIRCADIAN RHYTHM AND THE SCN 
The suprachiasmatic nucleus (SCN) in the mammalian hypothalamus orchestrates the 
organism’s circadian rhythms, such as the daily sleep/wake cycle, metabolism, and 
hormone release [1]. The SCN is a pair of bilateral nuclei positioned above the optic 
chiasm, with each nucleus consisting of approximately 10,000 cells. The SCN can 
adjust the body’s circadian rhythms so they align to the external environment in 
response to temporal cues such as light and temperature, contributing to the optimal 
health and survival of the organism [2]. Ablation of the SCN in rodents leads to the 
loss of rhythms in behavior such as wheel running and physiology such as body 
temperature fluctuations. To function as a time keeper, cells within the SCN must 
synchronize with one another to generate a coherent rhythm, which can then be 
communicated to other parts of the hypothalamus as well as the rest of the body [3]. 
 
1.2 CORE CLOCK PROTEINS 
At the core of circadian time keeping is the transcription-translation feedback loop 
(TTFL). The TTFL is present in all cells in the body, and provides the basis for the 
rhythmicity in expression of additional genes and cellular functions [4]. In mammals, 
the positive feedback loop includes CLOCK and BMAL1, which heterodimerize and 
induce the expression of the clock genes Period (Per1, Per2 and Per3) and 
Cryptochrome (Cry1 and Cry2). The negative feedback loop consists of PERIOD and 
CRY proteins, which heterodimerize to re-enter the nucleus and suppress the activities 
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of CLOCK and BMAL1. CLOCK and BMAL1 also induce the expression of retinoic 
acid-related orphan nuclear receptors REV-ERBα and RORα. REV-ERBα re-enters the 
nucleus and inhibits the expression of Bmal1, while RORα induces the expression of 
Bmal1. Together, the positive and negative elements of the feedback loop cycle on a 
period of around 24 h, thus setting the basis of the circadian clock [4]. Transgenic mice 
expressing PERIOD2::LUCIFERASE (PER2::LUC) fusion protein enable 
bioluminescence imaging of PER2 to directly monitor the phase of the TTFL [5].  
 
1.3 HUMORAL ENTRAINMENT IN THE SCN 
Previous experiments demonstrated that fetal SCN grafts encapsulated in membrane 
impermeable to neuronal processes can restore behavior and physiological circadian 
rhythmicity in hamsters with electrically ablated SCNs [6]. This result suggests that 
humoral signaling is a part of the SCN output to the hypothalamus and the rest of the 
organism. The inability of the graft to restore circadian endocrine rhythms of 
hormones released via the pituitary suggests that physical contact such as synaptic 
communication is also an important part of the SCN output.  
 
The SCN expresses a rich, heterogeneous collection of neuronal subtypes with region-
specific expression of peptides [7], number of which are implicated in circadian 
function. The SCN is conventionally divided into the ventrolateral and the dorsomedial 
sub-regions, designated by the peptides released and specific circadian network 
properties [7]. The cells of the ventrolateral SCN receive direct photic inputs via the 
retinohypothalamic tract (RHT) and release vasoactive intestinal peptide (VIP) in 
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response to light to synchronize the SCN [8–10]. The central sub-region in the 
ventrolateral SCN receives input from the RHT and secretes gastrin-releasing peptide 
(GRP) and little-SAAS [11,12]. The ventrolateral region relays signals to the 
dorsomedial SCN, which contains arginine vasopressin (AVP) neurons and is 
responsible for communicating the rhythm to the rest of the hypothalamus [7,13,14]. 
Dorsomedial SCN is also believed to be the location of the true circadian clock [14]. 
Knockout of VIP can result in loss of behavior rhythms and disrupted coordination 
among SCN neurons in mouse, suggesting a role in cell-cell synchronization. 
Exogenous VIP, GRP, and little-SAAS can alter the phase of rat SCN, each with a 
specific window of action [12,15,16]. Like the clock proteins in the TTFL, circadian 
peptides exhibit diurnal rhythms in expression and release. For example, mRNA level 
of AVP in the mouse SCN is high at dusk and low at dawn. VIP and GRP on the other 
hand, have mRNA levels that peak in the day and trough in the night [17]. Some of 
these rhythms are species-specific. For instance, GRP expression has no clear rhythm 
in the rat [17].  
 
1.4 DIFFERENT RHYTHMS AND PHASE-SHIFTING IN THE SCN 
Clock proteins and circadian peptides are not the only oscillating elements in the SCN. 
Daily rhythms in Ca2+ are also observed in the SCN [18,19]. Neurons and astrocytes in 
the SCN demonstrate Ca2+ rhythms that are in anti-phase [20]. SCN neurons fire 
spontaneously and the frequency of the firing peaks during the midday (ZT 7) [21]. 
The overall redox state of the SCN also oscillates daily, being more oxidized during 
the day and more reduced during the night [22]. Ca2+, spontaneous firing, and PER2 
4 
 
protein rhythms have strict phase relationships [19,20]. All three oscillations 
mentioned above are intrinsic to the SCN, and can be recorded for prolonged periods 
of time in organotypic SCN slice cultures ex vivo as in the PER2::LUC rhythm 
[20,22,23].  
 
The hallmarks of a biological clock are: A) in constant conditions the period of the 
oscillation is close but equal to 24 h, B) the free-running rhythm is temperature-
compensated, and C) the rhythm can entrain to external cues, such as the light/dark 
cycle [24]. The ability to phase-shift allows the SCN to adjust phase in reaction to 
external temporal cues. One example is the response to light and glutamate (GLU). 
GLU is the excitatory neurotransmitter that conveys photic cues from the RHT to the 
SCN. When applied to the SCN in vitro during the subjective day, GLU does not alter 
the phase of the SCN. In the early night GLU induces phase delay and in the late night 
induces phase advance. A phase-response curve (PRC) can be generated based on how 
the SCN reacts to GLU at different points of the phase. Light exposure in intact 
animals have similar phase-shifting effects [25]. The temporal difference in response 
to light and GLU enables entrainment of the SCN to changes in the light/dark cycle. In 
addition to GLU, the SCN is also known to phase-shifts in response to a number 
peptides and compounds. For example, peptides like VIP, NPY and little-SAAS can 
induce phase-shifts with different PRCs [12,26,27]. Compounds like melatonin, 





1.5 CBLN1, CEREBELLIN AND CEREBELLIN-SHORT 
Investigations of peptides in the SCN was advanced significantly when direct high-
resolution mass spectrometry-based peptidomics studies revealed 102 endogenous 
SCN peptides, 33 of which had been previously unidentified [32]. Several unexpected 
small peptides are found to be released in circadian fashion [33]. One such peptide is 
the 15 amino acid cerebellin-short, a C-terminus histidine truncated form of the full 
length 16 amino acid cerebellin peptide known to be richly expressed in the 
cerebellum [33,34]. There exists an alternative form of truncated cerebellin. Instead of 
the C-terminus histidine, the N-terminus serine is removed. The N-terminus serine-
truncated cerebellin is expressed in the cerebellum in comparable amounts to the full-
length peptide [34]. To avoid confusion, from this point forward cerebellin-short will 
always refer to the C-terminus truncated form while cerebellin refers to the full-length 
peptide. Although all three forms of cerebellin are present in the SCN [32,35], only 
cerebellin-short is released in a circadian pattern from the SCN in in vitro brain slices. 
Release of cerebellin-short showed a peak 4 h into the subjective night (CT 16) [33]. 
Cerebellin and cerebellin-short are proteolytic products of the full-length precursor 
protein, Cerebellin 1 (Cbln1), which has been found to be highly expressed in the 
cerebellum, and to lesser degrees in the forebrain and the spinal cord [36–39].  
 
Cbln1 is a member of the C1q family and is one of four Cbln proteins (Cbln1 to 
Cbln4), all of which contain C1q domain at the C-terminus [36]. The C1q domain is 
present in many secreted proteins and allows Cbln to form 3-fold symmetric 
homotrimers. Two conserved cysteine residues near the N-terminus enable 
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homotrimers of different Cbln to cross-interact and dimerize into a collection of 
hexamer complexes [40,41]. The combination of different Cbln homotrimers in the 
hexamer determines its downstream binding partners and function [42–45]. Cbln1 is 
the best studied Cbln protein, and is the only one out of the four known to be 
extensively processed into specific cerebellin peptide forms on top of its regular 
synapse forming functions.  
 
Cbln1 is known to bind to glutamate receptor δ 1 and 2 (GluRD1 and GluRD2) and 
several subtypes of neurexin β receptors [40,45–47]. GluRD1 and GluRD2 are orphan 
receptors that are identified through sequence homologies to other ionotropic 
glutamate receptor subunits but do not form functional ion channels [47,48]. GluRD2 
is highly expressed in the Purkinje cell of the cerebellum [49]. GluRD2-KO animals 
share similar synaptic and behavioral phenotypes with Cbln1 KO mice, an observation 
that later led to the discovery of the interaction between Cbln1 and GluRD2 [47]. 
GluRD1 is highly expressed in the adult  hippocampus and inner ear, but its function is 
not well understood [49]. Mutation or deletion of GluRD1 is associated with loss of 
high-frequency hearing as well as cognitive deficits and mental health disorders, such 
as schizophrenia [50–52].  
 
Cbln1 has well studied synaptic functions. Cbln1 protein is crucial for the formation 
and maintenance of excitatory synapses between the Purkinje cells (PC) and the 
parallel fibers (PF) in the cerebellum by interacting with presynaptic neurexin β and 
postsynaptic GluRD2 receptors [41,47]. Cbln1-KO animals are ataxic and have 
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significantly decreased number of PC-PF synapses. Injection of recombinant Cbln1 in-
KO animals rapidly restores PC-PF synapses and rescues the ataxic phenotype. This 
rescue is not permanent, demonstrating the dynamic nature of the role of Cbln1 in 
maintaining PC-PF synapses [53]. In cultured cortical neurons, Cbln1 contributes to 
the formation of inhibitory synapses [54]. In the forebrain Cbln1 likely contributes to 
the formation of both excitatory and inhibitory synapses in different regions. GluRD1 
is expressed in the hippocampus while Cbln1 is expressed in entorhinal cortical 
neurons that project to the hippocampus. Cultured entorhinal cortical neurons can form 
both excitatory and inhibitory axonal terminals on HEK cells expressing GluRD1, 
while cultured hippocampal neurons require the addition of recombinant Cbln1 to 
achieve the same effect [55]. These results suggest Cbln1 might contribute to synapse 
formation in the hippocampus through interaction with GluRD1.  
 
Cerebellin peptide has been reported to have diverse regulatory functions in the 
nervous system, although the mechanisms are not elucidated. Synthetic cerebellin has 
been shown to induce catecholamine release from human adrenal cells in vitro and 
norepinephrine release from rat adrenal gland in vivo [56,57]. Intracerebroventricular 
injection of synthetic cerebellin increases feeding behavior in rats, possibly by acting 
through one or more hypothalamic nuclei [58]. Spinal injection of the N-terminus 
serine-truncated cerebellin leads to mechanical hypersensitivity in mouse [38]. 
 
Unlike Cbln1, cerebellin peptides have no known receptors. The lack of critical 
cysteine residues and the intact C1q domain preclude interaction with known Cbln1 
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binding partners [36,40,59].  Compared to Cbln1, studies on cerebellin are scarce 
possibly due to several reasons. Traditional antibody-based detection methods such as 
immunohistochemistry cannot effectively distinguish cerebellin from its precursor 
Cbln1 due to overlap in amino acid sequences. The existence of multiple processing 
intermediates further complicates the analysis. At approximately 1.5 kDa, endogenous 
concentration of cerebellin cannot be resolved on a Western blot. All of these issues 
make Cbln1 the more attractive choice of study. Nevertheless, Cbln1 and cerebellin 
present an intriguing case where the precursor and the processed peptide have very 
different functions. The possible involvement of cerebellin-short in circadian time 
keeping adds another dimension to this curious dichotomy. Full-length cerebellin and 
the two forms of truncated cerebellin are all endogenous to the rat SCN as shown by 
mass spectrometry analysis [35]. However, whether Cbln1, cerebellin or cerebellin-
short are involved in SCN timekeeping has been unknown.  
 
1.6 STATEMENT OF PROBLEMS AND SIGNIFICANCE 
The goal of this investigation is to characterize the expression, localization, and 
circadian function of cerebellin-short in the rat SCN. Based on the circadian release of 
cerebellin-short from the rat SCN, I hypothesize that cerebellin-short undergoes cell 
type-specific circadian expression in sub-regions of the rat SCN and exerts a circadian 
function through mechanism different from Cbln1. In this study, I examined the 
expression profiles of cerebellin-short and the precursor Cbln1 in the SCN. I 
investigated the circadian functions of cerebellin-short in phase-shifting the SCN 
spontaneous neuronal firing rhythm. I also characterized the region-specific 
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localizations of cerebellin-short processing intermediate and the precursor Cbln1 
within the SCN. 
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CHAPTER TWO: CHARACTERIZING CEREBELLIN-SHORT, A 
NOVEL CIRCADIAN PEPTIDE, IN THE RAT 
SUPRACHIASMATIC NUCLEUS 
2.1 ABSTRACT 
The suprachiasmatic nucleus (SCN), the central circadian clock in mammals, contains 
a number of peptides important for synchronizing the intrinsic rhythm and conveying 
it to other parts of the brain. Cerebellin-short (SGSAKVAFSAIRSTN) is a small 
peptide consisting of 15 amino acids identified in mass spectrometry proteomics 
secreted from the SCN in circadian fashion. Cerebellin-short is the C-terminus 
histidine- truncated form of 16 amino acid full-length cerebellin, a peptide enriched in 
cerebellum. The distribution and function of cerebellin-short in the SCN, however, are 
unknown. Here we show that Cbln1, the precursor for cerebellin, is expressed in the 
SCN with daily oscillations in mRNA and peptide processing intermediates. 
Immunoreactivity in the SCN of anti-cerebellin-short showed different localization 
patterns compared to precursor Cbln1. Exogenous cerebellin-short applied at midday 
and early night phase advance the spontaneous firing rhythm of SCN neurons. These 
results suggest that endogenous cerebellin-short contributes a circadian regulatory 
function. Cerebellin-short, therefore, is likely involved in the intrinsic circadian time-






The suprachiasmatic nucleus (SCN) in the mammalian hypothalamus orchestrates the 
organism’s circadian rhythms, such as the daily sleep/wake cycle, metabolism, and 
hormone release [1]. The SCN is able to adjust the body’s circadian rhythms so as to 
align to the external environment in response to temporal cues such as light from the 
day/night cycle, contributing to the health and survival of the organism [2]. To function 
as a timekeeper, cells within the SCN must synchronize with one another to generate a 
coherent rhythm, which can then be communicated to the rest of the hypothalamus [3]. 
The SCN expresses a rich, heterogeneous collection of neuronal subtypes with region-
specific expression of peptides [4], a number of which have been shown to be involved 
in circadian timekeeping. The cells of the ventrolateral SCN receive photic inputs via 
the retinohypothalamic tract (RHT) and release vasoactive intestinal peptide (VIP) in 
response to light to synchronize the SCN [5–7]. The central sub-region in the 
ventrolateral SCN receives input from RHT and secretes gastrin-releasing peptide 
(GRP) and little SAAS [8,9]. Knockout of VIP can result in loss of behavior rhythms 
in the mouse, suggesting a role in cell-cell synchronization. VIP, GRP, and little SAAS 
can alter the circadian timing of rat SCN, each with a specific window of action [9–
11]. 
 
Investigation of peptides in the SCN was advanced significantly when direct high-
resolution mass spectrometry-based peptidomic studies revealed 102 endogenous SCN 
peptides, 33 of which had been previously unidentified [12]. A number of unexpected 
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small peptides were also found to be released in a circadian fashion [13]. One such 
small peptide is the 15 amino acid cerebellin-short (SGSAKVAFSAIRSTN), a C-
terminus histidine truncated form of the 16 amino acid cerebellin peptide 
(SGSAKVAFSAIRSTNH) known to be richly expressed in the cerebellum [13,14]. 
Cerebellin-short was released in a circadian pattern from the SCN brain slice; peak 
release was 4 h into the subjective night of the SCN in vitro. Cerebellin and cerebellin-
short are proteolytic products of Cerebellin 1 (Cbln1) (Fig. 2.1), which has been found 
to be expressed in both the forebrain and the cerebellum [15,16]. Cbln1 and full-length 
cerebellin peptide have been reported to have diverse regulatory functions in neurons. 
Cbln1 protein is crucial for the formation and maintenance of excitatory synapses 
between the Purkinje cells and the parallel fibers in the cerebellum [17,18]. In cultured 
cortical neurons, Cbln1 contributes to the formation of inhibitory synapses [19]. 
Synthetic full-length cerebellin peptide has been shown to induce catecholamine 
release from human adrenal cells in vitro and norepinephrine release from rat adrenal 
gland in vivo [20,21]. Intracerebroventricular injections of full-length cerebellin 
peptide increases feeding behavior in rats [22]. However, whether Cbln1, cerebellin, or 
cerebellin-short are involved in SCN timekeeping remains unknown. In this study we 
examined temporal and spatial patterns of Cbln1 within the SCN. Further, we 





2.3 MATERIALS AND METHODS 
Animal 
Long Evans/BluGill rats of both genders (University of Illinois, Urbana, IL) between 
the ages of 7 to 13 weeks were used for adult rat experiments. The colony is inbred, 
and genomic scan revealed one allele at each locus examined. Rats are housed under 
12h:12h light-dark cycle with constant temperature, humidity, and food and water ad 
libtium. Zeitgeber time (ZT), standardized to the environmental light cycle, is 
designated ZT 0 when the light turns on and ZT 12 when the light goes off.  
 
Tissue acquisition   
For Western blot and quantitative RT-PCR analysis, unanesthetized animals were 
decapitated by guillotine at designated ZT times and the brain quickly extracted. The 
hypothalamus was surgically reduced and a 500 μm thick coronal slice containing the 
SCN, the third ventricle, and the optic chiasm was prepared using fresh razor blades 
and a mechanical tissue chopper. A tissue puncher (r = 1.5 mm) was used to isolate the 
SCN from the slice, followed by flash freezing over dried ice. Cerebellum punch (r = 
1.5 mm, 500 μm thick) were collected from the same brain and flash frozen over dried 
ice.  
 
For fixed tissue collection, animals were euthanized with 1 ml Euthasol (Virbac, Fort 
Worth, TX) at designated ZT times and perfused through the heart with 300 ml of 
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0.9% saline, followed by 300 ml of 4% paraformaldehyde (PFA) in 0.1 M PBS. The 
brain was removed and fixed in 4% paraformaldehyde overnight at 4 °C, then 
transferred to 30% sucrose solution in PBS for 72 hrs at 4 °C for cryo-protection. 
Coronal brain sections (40 μm) were obtained by cryostat (Microm). 
 
Real-time qRT-PCR 
Total RNA was extracted with TRIzol reagent (Invitrogen) followed by ethanol 
precipitation. RNA quantity and purity were assessed by 260 nm/280 nm absorbance. 
Reverse transcription of 500 ng total RNA with random hexamer primers was 
performed with SuperScript III Reverse Transcriptase (Invitrogen) in duplicates at 50 
°C for 1 h, then terminated at 70 °C for 10 min. Quantitative PCR was performed with 
iQ SYBR Green Supermix (Bio-Rad) with 300 nM primers in MicroAmp 96-well 
plates (Life Technologies) on StepOne Real-Time PCR System (Life Technologies). 
Denaturation was performed at 95 °C for 10 min, followed by 40 cycles of 94 °C for 
15 s and 60 °C for 1 min. A melting curve was constructed at the end of the last cycle. 
Triplicates of identical reactions were set up for the real-time PCR to control for 
pipetting errors. Data was analyzed in StepOne Software (Life Technologies). Results 
were presented as relative expression levels compared to a stably expressed 
housekeeping ribosomal protein transcript (acidic ribosomal protein, NM022402) [23], 
and normalized to ZT 16. Primer sets span across intron gaps to avoid amplification of 






Forward 5’- CCAGGTACTAGTGAACATCGGG -3’ 
Reverse 5’- TCAGAGGGGAAACACGAGGAATC -3’ 
GFAP (NM017009) 
Forward 5’- ATGGCATCACCATTCCTGTAC -3’ 
Reverse 5’- TGGCCTTCTGACACCGATTT -3’ 
Acidic ribosomal protein (NM022402) 
Forward 5’- CGTGATGCCCAGGGAAGA -3’ 
Reverse 5’- TCCACAATGAAGCATTTTGG -3’ 
 
Synthetic peptide and antiserum 
Cerebellin, cerebellin-short, and scrambled cerebellin-short peptides were synthesized 
by GenScript or the Carver Biotechnology Center (University of Illinois). Synthesized 
cerebellin-short peptide was used as the epitope to generate rabbit anti-cerebellin-short 
antisera (UIUC Immunological Resource Center). The anti-sera was affinity purified 
with the EpiMAX Affinity Purification Kit (Abcam) using synthetic cerebellin peptide 
as antigen. Specificity for cerebellin-short was confirmed by reactivity against 
synthetic cerebellin-short, but not scrambled peptide. A single band at ~15 kDa is 
21 
 
detected by the affinity purified anti-sera from rat brain tissue lysates, corresponding to 
the predicted molecular weight of the C-terminus portion of Cbln1 when cleaved at the 
beginning of the cerebellin sequence (Fig. 2.1B). Strong punctate staining near the 
Purkinje cell layer of the cerebellum further confirms the specificity of the anti-sera. 
 
Western blot 
Total protein (15 μg) was resolved on 12% SDS-PAGE and transferred to 
polyvinvldifluoride (PVDF) membrane (Bio-Rad, Hercules, CA). Cbln1 and cleavage 
products were detected with either 1:1,000 dilution of rabbit polyclonal anti-
precerebellin antibody (PA5-20159, Thermo Fisher) or 1:1,000 cerebellin-short 
antisera, followed by 1:2,500 dilution of HRP-conjugated goat anti-rabbit antibody 
(Invitrogen), and visualized with SuperSignal West Femto Maximum Sensitivity 
Substrate (Thermo Fisher). The membrane was then subjected to 1:10,000 dilution of 
rabbit anti-GAPDH antibody (G-9545, Sigma-Aldrich), followed by 1:2,500 HRP-
conjugated goat anti-rabbit antibody (Invitrogen) and visualized. Protein levels were 




To localize Cbln1/cerebellin-short in the SCN, 40 μm coronal brain sections were 
antigen retrieved for 30 min at 75 °C in 10 mM sodium citrate (pH 9) then blocked in 
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0.3% Triton X-100 PBS with 5% normal goat serum (Vector Labs) or normal donkey 
serum (Jackson ImmunoResearch) at room temperature for 1 h. Tissue was exposed to 
either 1:1,000 rabbit anti-Cbln1 (ab92526, Abcam) or 1:2,000 affinity-purified rabbit 
anti-cerebellin-short anti-sera in 0.3% Triton X-100 PBS with 2% normal goat serum 
or normal donkey serum for 48 h at 4 °C. Sections were washed with PBS and stained 
for 1 h at room temperature in 0.3% Triton X-100 PBS with 2% normal goat serum or 
donkey serum containing appropriate 1:1,000 Alexa Fluor dyes that emit at 488, 568 or 
594 (Life Technologies). To visualize the nuclei, sections were stained with 
diamidinophenylindole (DAPI), washed in PBS and mounted on gelatin-coated 
Superfrost microscope slides. Once dried, slides were coverslipped with Prolong Gold 
Antifade (Life Technologies).  
 
Image acquisition 
Immunofluorescence images were captured on a LSM-710 confocal microscope 
(Zeiss, Oberkochen, Germany). Image acquisition parameters (gain, offset, scan 
properties and laser power) were optimized for each objective lens and kept constant 
across samples examined. Captured images were compiled in Zen2 and Adobe 
Photoshop CC software with minimum alteration.  
 
Single unit activity recording 
Unanesthetized animals were decapitated by guillotine and brains quickly extracted. 
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The hypothalamus was reduced to 500 μm rectangular coronal slice containing the 
SCN, the third ventricle and the optic chiasm using fresh razor blades and a 
mechanical tissue chopper. The slice was maintained in a large-volume brain slice 
chamber perfused with Earle’s balanced salt solution (EBSS, HyClone) supplemented 
with glucose, bicarbonate and Gentamicin [25]. The chamber was maintained at 
constant temperature of 37 °C and the EBSS was saturated with 95% O2:5% CO2. 
SCN neurons maintain a rhythm of single unit activity (SUA) in vitro that peaks 
around circadian time 7 (CT 7). CT designates the subjective time of day with 
reference to the intrinsic circadian clock. SUA of an SCN neuron was recorded for 4 
min with glass electrodes filled with 5 M NaCl solution; at least 4 neurons were 
recorded per 60 min [26]. Activities of slices were recorded for 8 h starting at CT 0. 
Slices were prepared the day before recording during daytime to avoid shifting the 
intrinsic rhythm associated with cutting the optic nerve during the night. The activities 
were then averaged over 2 h with 15-min sliding windows and plotted using 
SigmaPlot. Treatment with peptide was performed by stopping the EBSS flow and 
filling the chamber for 10 min with EBSS containing the peptide at designated CT 
times. After 10 min, the EBSS containing peptide was withdrawn and the chamber 
refilled with regular EBSS, flow was then resumed.  
 
Statistical analysis 
Statistical analysis was performed using the GraphPad Prism 6 Software. One-way 
ANOVA with Dunnett’s multiple comparisons test was used to compare magnitudes of 
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phase-shifts between treatments and control. One-way ANOVA with Bonferroni’s 
multiple comparisons test was used for Western blots and qRT-PCR. P ≤ 0.05 was 
considered statistically significant. 
 
2.4 RESULTS 
Cbln1 cleavage product in the rat SCN peaks during midday 
Cerebellin is the proteolytic product of Cbln1 [27]. Western blot analysis of the SCN at 
six time points around the day did not show a significant change in the levels of Cbln1 
monomer (MW = 25 kDa) when normalized to the non-circadian GAPDH (Fig. 2.2) 
[28]. On the other hand, the 15 kDa cleavage product of Cbln1 monomer peaks in 
midday (ZT 8) when compared to three other time points around the day when 
normalized to GAPDH (P ≤ 0.05, n = 4) (Fig. 2.2). The level of the 15 kDa Cbln1 
cleavage product did not oscillate in the cerebellum (data not shown). The daily peak 
in the cleavage product, but not the full length Cbln1, indicates diurnal oscillation in 
peptide cleavage and processing. Specificity of the anti-sera is demonstrated by its 
immunoreactivity against synthetic cerebellin-short peptide, which was used as the 
epitope to generate the anti-sera. Anti-sera showed no immunoreactivity against the 
scrambled control peptide. Possibly due to its small size (Predicted MW = 1.4 kDa) 





Cbln1 mRNA in the rat SCN increases during late night 
To determine whether oscillating levels of cerebellin-short released from the SCN is 
also controlled at the level of translation, qRT-PCR for Cbln1 mRNA was performed 
using published primer sets [24]. Cbln1 mRNA levels in the SCN is significantly 
elevated at late night (ZT 20) compared to three other time points around the day when 
normalized to the non-circadian housekeeping acidic ribosomal protein (Fig. 2.3).  
 
Affinity purified anti-sera immunoreactivities in the rat SCN are punctate and 
different from localization of Cbln1 
To determine the spatial expression of Cbln1 and cerebellin-short in the SCN, 
immunohistochemistry was performed with either affinity-purified anti-cerebellin-
short anti-sera or an antibody against Cbln1. Cerebellin-short anti-sera 
immunoreactivity appeared punctate in the cell bodies throughout the SCN (Fig. 2.4A-
C). Immunoreactivity appeared punctate and were restricted to the cell bodies, with no 
staining in processes observed. Cbln1 immunoreactivity on the other hand, showed 
process-like staining and was localized immediately outside of dorsal SCN along the 
3rd ventricle (Fig. 2.4D-F). To determine the temporal pattern of Cbln1 expression in 
the SCN, DAB immunohistochemistry was performed on fixed coronal brain slices at 
six different time points around the day-night cycle with the cerebellin-short anti-sera. 
DAB staining in the SCN with the cerebellin-short anti-sera does not appear to vary 
over the day (data not shown). 
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Cerebellin-short advances the phasing of the rhythm of spontaneous neuronal 
activity in the rat SCN in vitro. 
In vitro SCN has the ability to maintain spontaneous neuronal activity rhythm, which 
peaks around mid-day (CT 6.75 ± 0.07; Fig. 2.5A, I) [29]. To investigate whether 
cerebellin-short, the released form of the peptide, has a functional effect on the 
circadian time-keeping, synthetic cerebellin-short (100 nM) was applied to the SCN 
brain slice at CT 7, 14, or 21. These times represent subjective mid-day, early night, 
and late night, respectively. Synthetic cerebellin-short applied at CT 7 induced a 
significant phase advance in the SCN spontaneous neuronal activity rhythm (CT 3.75 
± 0.20; n=3; P≤0.001; Fig. 2.5B, E). When applied at CT 14, cerebellin-short also 
significantly phase advanced the neuronal activity rhythm (CT 4.75 ± 0.54; n=3; 
P≤0.01; Fig. 2.5C, E). The same treatment at CT 21 did not phase shift the SCN (Fig. 
2.5D, E). Scrambled peptide did not induce a phase-shift at CT 7 (Fig. 2.5E). 
Treatment at CT 7 with full-length cerebellin peptide also induced phase-shift at 
similar magnitude as cerebellin-short (Fig. 2.5E). 
 
2.5 DISCUSSION 
Cbln1 and cerebellin-short present an interesting case where both the precursor and the 
processed peptide were previously shown to have unique functions in biological 
systems [18,20,21,30]. This study presents, for the first time, a functional role for the 
cerebellin-short peptide, as a potential circadian peptide in the rat SCN. 
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Circadian expressions of Cbln1 mRNA and CBLN1 protein in the rat SCN 
suggest it is controlled by the circadian clock 
Previous studies that examined general expression in the mouse brain did not report 
Cbln1 mRNA or protein in the SCN [16,24]. However, since Cbln1 mRNA and protein 
processing oscillate throughout the day, it is possible that previous investigations 
happened to capture the trough of expression. Alternatively, samples could have been 
gathered at multiple times of the day, which resulted in data with high variance and 
was, therefore, regarded as experimental error. Also both studies were performed in 
mouse, which are physiologically and genetically distinct from rats. Here we 
demonstrate that Cbln1 mRNA and protein are present in the rat SCN. Both Cbln1 
mRNA and protein processing undergo daily oscillations in the SCN, suggesting that 
Cbln1 transcription and processing are under influence of the circadian clock.  
 
Sequential peaks of mRNA vs. protein levels suggest additional controls in 
translation and/or peptide processing 
Our results show that Cbln1 mRNA is present in the SCN at uniform levels throughout 
the course of the day, but becomes significantly elevated in late night (ZT 20). 
Although not statistically significant, full length Cbln1 monomer showed a trend of 
reduced RNA levels from ZT 0 to ZT 20. Interestingly, the 15 kDa cleavage product of 
the full length Cbln1 showed a significant peak at ZT 8, which is 12 h apart from the 
mRNA peak. The same oscillation is not observed in the cerebellum, where the level of 
15 kDa cleavage product stayed constant. It has previously been observed that the 25 
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kDa Cbln1 monomer is unstable and easily cleaved at the N-terminus of the cerebellin 
motif into the 15 kDa cleavage product (Fig. 2.1B) [28]. The mismatch of the two 
profiles, where only the transcription level is elevated at ZT 20, suggests additional 
levels of control at either or both translation and/or degradation. A previous study 
utilizing MS, recorded an oscillation in release of endogenous cerebellin-short from 
the rat SCN, peaking in the subjective mid-night (CT 16) [13]. This is 8 h after the 15 
kDa cleavage product peak at ZT 8 (Fig. 2.2). This suggests that the rate at which 
Cbln1 is processed into cerebellin and/or cerebellin-short is controlled at the post-
translational level and is independent of the abundance of the Cbln1 protein. Also 
Cbln1 is not likely processed entirely into cerebellin intracellularly. Previous studies in 
the cerebellum and in cultured cortical neurons showed that functional Cbln1 forms 
homohexamer or heterohexomers with Cbln2 or Cbln3, and may be secreted in an 
uncleaved form to facilitate synapse formations and maintenance [15,18,19,31]. Even 
if the SCN does release Cbln1, previous MS-based peptidomics studies would not have 
registered uncleaved Cbln1 since at 193 amino acids it is too large for the detection 
range designated for peptides [15]. Whether uncleaved Cbln1 is also released in the 
SCN with potential synaptic and/or circadian implications is a subject for further 
investigation. 
 
Cbln1 immunoreactivity showed different localizations from anti-cerebellin-short 
immunoreactivity 
Cbln1 immunoreactivity is localized immediately dorsal of the SCN along the 3rd 
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ventricle and demonstrates fibrous staining. Whereas anti-cerebellin-short 
immunoreactivity is punctuated and localize to the cell bodies throughout the SCN. 
These staining patterns suggest that immediately outside of the SCN, a portion of 
Cbln1 remains unprocessed and perhaps functions through the known process of 
hexamerization and secretion. In the rest of the SCN, Cbln1 might be readily degraded 
or processed into cerebellin or cerebellin-short to exert the peptide-specific function.  
 
Cerebellin-short advances phasing of the SCN during the day and early night  
Exogenous cerebellin-short peptide applied to the SCN brain slice in subjective mid-
day (CT 7) and early night (CT 14) phase advanced the intrinsic SCN neuronal firing 
rhythm. Endogenous release of cerebellin-short at these two times from the SCN is 
low, suggesting a functional role of cerebellin-short in the circadian signaling within 
the SCN when the system is perturbed. Despite the growing literature on Cbln1 and the 
identifications of several Cbln1 receptors (Nrxnβ, GluRD1, GluRD2) [18,19], a 
receptor has yet to be identified for cerebellin or cerebellin-short. Known Cbln1 
receptors cannot function as cerebellin or cerebellin-short receptors. The domains 
involved in the formation of functional Cbln1 hexomers required for binding to these 
receptors are removed when cerebellin and cerebellin-short are formed [15,18,32]. 
Recent crystallography studies also show that domains on the Cbln1 that interact with 
GluRD2 and Nrxn are outside of the cerebellin motif [28,32]. Whether cerebellin-short 
exerts its circadian effects through a receptor or via other mechanisms remains a 
question. The timing of SCN sensitivity to cerebellin-short is not unique. Melatonin 
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and serotonin elicit phase advances when applied to the rat SCN in the early night and 
midday respectively [33,34]. Since cerebellin-short also elicits phase advance at these 
two times of the day, it could signal through related pathways. Whether these 
regulators of SCN phasing are functionally related requires investigation.  
 
How the full-length Cbln1 is processed into cerebellin peptide is still unclear 
This study identifies the presence of Cbln1 in the SCN and identifies cerebellin-short 
as a novel circadian peptide. However, many questions remain. The proteolytic events 
generating cerebellin and cerebellin-short from Cbln1 are unclear, and the 
identification of multiple intermediates suggests the process is complex [15]. Cbln1 is 
either secreted intact or processed into the cerebellin peptides. Whether these two 
pathways are exclusive or takes place in the same cell is unknown in the SCN. If both 
pathways exist in the same cells, then it requires intricate control to balance the levels 
of Cbln1 and cerebellin peptides. In addition, the 16 amino acid cerebellin peptide also 
elicited phase shift on the SCN, showing redundancy with cerebellin-short in circadian 
function. The extra histidine on cerebellin may contribute to longer half-life of the 
peptide compared to cerebellin-short, providing another level of control. Cbln1 is 
unusual in that it is transported between cell types in the cerebellum from the granule 
cells and to the Purkinje cells and the Bergmann glia [35], begging the question 
whether similar events take place in the SCN and is related to the production, release 






Figure 2.1. Full length amino acid sequence and domains of Cbln1. (A) Amino 
acid sequence of full length 193 amino acid rat Cbln1 (NP 001102597) [36]. 16 amino 
acid cerebellin peptide sequence is highlighted in yellow, red box designates C-
terminus Histidine truncated from cerebellin-short. Green boxes designate 
glycosylation sites of Cbln1 at Arginine 23 & 79. Black boxes designate Cystine 34 & 
38 responsible for dimerization of Cbln1 [15]. Black underline designates the signal 
peptide sequence. (B) Schematic of Cbln1, with C-terminus signal peptide and N-
terminus C1q motif. Predicted molecular weights base on amino acid sequences of full 







Figure 2.2. Cbln1 mRNA exhibit diurnal variations in the rat SCN. (A) Cbln1 
mRNA level is uniform from dawn (ZT 0) through early night (ZT 16), but is elevated 
in the late night (ZT 20) compared to ZT 0, ZT 4 and ZT 12. Graph shows mean ± 
SEM, one-way ANOVA with Bonferroni’s multiple comparisons test, * P ≤ 0.05 ** P ≤ 
0.01, n = 4. ZT 0 is double plotted to show complete 24 h. (B) Representative agarose 
gel of Cbln1 qRT-PCR products at each time point shown in duplicates, along with the 





Figure 2.3. The 15 kDa cleavage product of Cbln1 protein exhibits diurnal 
variations in the rat SCN, while the full length Cbln1 levels remain stable. (A) 
Levels of full-length Cbln1 (green) showed no significant variation throughout the day. 
Levels of the 15 kDa cleavage product (blue) is significantly elevated at midday (ZT 8) 
compared to ZT 0, ZT 16 and ZT 20. Plotted are means ± SEM, one-way ANOVA with 
Bonferroni’s multiple comparisons test, * P ≤ 0.05, n = 4. ZT 0 is double-plotted to 
show complete 24 h. (B) Representative Western Blot of full length Cbln1, the 15 kDa 
cleavage product and GAPDH from the same blot are shown beneath corresponding to 









Figure 2.4. Anti-cerebellin-short and Cbln1 immunoreactivities in the rat SCN 
show different localizations. Confocal image of ZT 8 medial caudal SCN 
immunostained with anti-cerebellin-short anti-sera (A) or anti-Cbln1 (D) (red), and 
DAPI (B and E) (blue). When merged, anti-cerebellin-short immunoreactivity showed 
punctate staining in the cell bodies throughout the SCN (C). Anti-Cbln1 on the other 
hand, showed fibrous staining immediately dorsal to the SCN along the 3rd ventricle 






Figure 2.5. Treatment with synthetic cerebellin-short peptide at CT 7 and CT 14 
phase advances the circadian rhythm in SCN neuronal activity. (A) SCN 
extracellular single unit recording of spontaneous neuronal firing rate peaks at CT 6.75 
± 0.07 (indicated by the vertical dotted line.) (B, C) Brief application of a synthetic 
cerebellin-short peptide (SGSAKVAFSAIRSTN, 100 nM, 10-min bath application) at 
CT 7 or CT 14 advances the phase of neuronal activity. (D) Treatment at CT 21 has no 
effect on the neuronal firing peak. Orange arrow: treatment time. Red arrow: phase 




Figure 2.5 (cont.). Treatment with synthetic cerebellin-short peptide at CT 7 and 
CT 14 phase advances the circadian rhythm in SCN neuronal activity. (E) Mean 
data for effects of the synthetic cerebellin-short peptide or the scrambled peptide (n = 
3). Treatment at CT 7 and CT 14 phase advances the rat SCN neuronal firing peak 
significantly (CT 3.75 ± 0.20 and C T4.75 ± 0.54, respectively) compared to the 
control time-of-peak (CT 6.75 ± 0.07). Neither the same treatment at CT 21 nor 
treatment with scrambled peptide (100 nM, 10-min bath application) at CT 7 altered 
phasing of this rhythm. Treatment with synthetic cerebellin peptide (100 nM, 10-min 
bath application) at CT 7 induced phase shift similar to cerebellin-short. Graph shows 
mean ± SEM, One-way ANOVA with Dunnett’s post-test, *** P≤0.001 **** P≤0.0001 
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CHAPTER THREE: LOCALIZATION AND PROCESSING OF 
CEREBELLIN-SHORT AND CBLN1 IN THE RAT 
SUPRACHIASMATIC NUCLEUS 
3.1 ABSTRACT 
Mammalian circadian rhythm is controlled by the suprachiasmatic nucleus (SCN), 
which expresses a rich collection of neuropeptides, number of which are crucial for 
synchronizing the intrinsic rhythm as well as the rhythm in the rest of the brain. One of 
such small peptide, cerebellin-short, is generated from the cleavage of Cbln1 and 
undergoes circadian release from the SCN. Cerebellin-short can phase shift the SCN 
when applied exogenously, yet the source and distribution of cerebellin-short and the 
precursor Cbln1 in the SCN is unknown. Here we show that cerebellin-short is present 
in both the AVP- and the VIP-positive cells in the SCN. Cbln1 on the other hand 
localized to fibers immediately dorsal to the SCN along the 3rd ventricle. Cbln1 is also 
prominent in the axons and cell bodies of magnocellular neurons in the paraventricular 
nucleus (PVN) and the supraoptic nucleus (SON). Upon synaptosome fractionation, a 
15 kDa cleavage product of Cbln1 is enriched in both the SCN and the cerebellum. 
These results suggest that Cbln1 is rapidly processed into cerebellin-short at the 
synapse and widely distributed in the SCN. Uncleaved Cbln1 may also serve functions 
in the PVN and the SON distinct from the circadian modulation by cerebellin-short in 





Circadian rhythms in mammals are controlled by the suprachiasmatic nucleus (SCN), a 
bilateral nucleus located in the base of the hypothalamus immediately above the optic 
chiasm [1]. Containing ~10,000 cells, the architecture of the SCN is complex, with 
interconnected sub regions defined by neuropeptide profiles and specific network 
properties [2]. The SCN is conventionally divided into a core region or the 
ventrolateral SCN, and a shell region or the dorsomedial SCN [2]. Ventrolateral SCN 
is characterized by the expression the vasoactive intestinal peptide (VIP), and is 
innervated by the retinohypothalamic tract (RHT) to receive direct photic input from 
the retina [3–5]. Upon light stimulation, glutamate (GLU) and pituitary adenylate 
cyclase-activation peptide (PACAP) released from the RHT leads to the secretion of 
VIP, a peptide known to synchronize the SCN [3,5]. Deletion of VIP or its receptor 
VPAC2 leads to impaired behavior rhythms and the loss of synchrony, highlighting the 
importance of VIP in circadian time keeping [6–8]. The dorsomedial SCN receives 
innervations from the ventrolateral SCN and is characterized by the expression of 
arginine vasopressin (AVP) [2,9,10]. The dorsomedial SCN acts as an output, with the 
circadian rhythm communicated to the rest of the brain [11,12]. Tempering with the 
core clock components Bmal1 or casein kinase 1 δ (CK1δ) in the AVP cells have 
consequences in the amplitude and period of the SCN rhythm, demonstrating the 
importance of functional AVP cells in circadian time keeping [13,14]. Neuropeptides 
can influence the circadian clock by phase-shifting the internal rhythm of the SCN. For 
example, VIP and gastrin releasing peptide (GRP) both phase-shift the SCN similar to 
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the light response [15–17]. Recently it was discovered that little SAAS, a cleavage 
product of ProSAAS highly expressed in the central region of the SCN, induces phase-
delay in the early night [18,19]. In the previous chapter, it was shown that cerebellin-
short can phase-advance the SCN both during the day and in the early night.   
 
In the hypothalamus, SCN interacts with other hypothalamic nuclei to control 
homeostasis, hormone secretion and metabolism (reference). SCN efferent innervate 
other hypothalamic nuclei including the paraventricular nucleus (PVN), the supraoptic 
nucleus (SON) and the arcuate nucleus (ARC) [11,12,20,21]. SCN also receives 
neuropeptide Y (NPY) and GABA through innervations from the intergeniculate 
leaflet (IGL), serotonin from the raphe nuclei, and melatonin from the pineal gland 
[2,9,22]. NPY, GABA, serotonin and melatonin serve as inputs and exert phase-shifts 
in the SCN with specific windows of action [23–28]. 
 
Cerebellin-short was discovered in high throughput mass spectrometry screening of 
releasate from the SCN with a circadian release pattern peaking during the middle of 
the night [19,29]. Cerebellin-short is the 15 amino acid cleavage product of the 
precursor protein Cbln1. Cbln1 has well established formation and maintenance 
functions in the cerebellum parallel fiber-Purkinje cell synapses [30–32], and has 
recently been implicated to participate in synapse formation in the hippocampus 
[33,34]. Previous low resolution whole brain in situ hybridization and immunostaining 
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studies suggested that Cbln1 is widely expressed in the hypothalamus [35–37], yet 
little follow up study has been done on Cbln1 in this region of the brain. Since 
cerebellin-short is released from the SCN, the precursor Cbln1 is either endogenously 
expressed in the SCN or transported to the SCN via afferents. In the cerebellum, Cbln1 
undergoes complex processing with multiple intermediates to yield cerebellin peptides 
[38]. Whether the same process takes place at the SCN is unknown. 
 
This study describes the difference in localization between Cbln1 and its processing 
intermediate in the rat hypothalamus. Region-specific distributions of cerebellin-short 
in the SCN were explored, and the subcellular distribution of Cbln1 versus processing 
intermediates in the SCN was examined.  
 
3.3 MATERIALS AND METHODS 
Animal 
Long Evans/BluGill rats of both genders (University of Illinois, Urbana, IL) between 
the ages of 7 to 13 weeks were used for adult rat experiments. The colony is inbred, 
and genomic scan revealed one allele at each locus examined. Rats are housed under 
12h:12h light-dark cycle with constant temperature, humidity, with access to food and 
water ad libtium. Zeitgeber time (ZT), standardized to the environmental light cycle, is 




Tissue acquisition   
For synaptosomal fractionation experiments, unanesthetized animals were decapitated 
by guillotine at ZT 8 and the brain quickly extracted. The hypothalamus was surgically 
reduced to a 1 mm thick coronal slice containing the SCN, the third ventricle and the 
optic chiasm using fresh razor blades on a mechanical tissue chopper. A tissue puncher 
(r = 1.5 mm) was used to isolate the bilateral SCN from the slice, which is 
immediately submerged in 9 volumes of chilled homogenizing media (0.32 M sucrose, 
50 mM Tris-HCl, pH 8) containing protease and kinase inhibitor cocktails. Cerebellum 
tissue was obtained from the same brain by reducing the cerebellum into a 1 mm thick 
sagittal slice.  
For fixed tissue collection, animals were euthanized with 1 ml Euthasol (Virbac) at 
designated ZT times and perfused through the heart with 300 ml of 0.9% saline, 
followed by 300 ml of 4% paraformaldehyde (PFA, Sigma-Aldrich) in 0.1 M PBS. 
The brain was removed and fixed in 4% PFA overnight at 4 °C, then transferred to 
30% sucrose solution in PBS for 72 hrs at 4 °C for cryo-protection. Coronal brain 
sections (40 μm) were obtained by cryostat (Microm).  
For fixed tissue from the Astrobow mice, adult animals were euthanized with 0.1 ml 
Euthasol and perfused through the heart with 50 ml of 0.9% saline, followed by 50 ml 
of 4% PFA in 0.1 M PBS. The brain was removed and fixed in 4% PFA overnight at 4 





To examine possible region-specific localizations of Cbln1/cerebellin short in the 
SCN, 40 μm coronal brain sections were antigen retrieved with 10 mM sodium citrate 
(pH 9) at 75 °C for 30 min [39]. Treated slices were blocked in 0.3 % Triton X-100 
PBS with 5 % normal goat serum (Vector Lab) or normal donkey serum (Jackson 
ImmunoResearch) at room temperature for 1 h. Slices were exposed to either 1:1,000 
rabbit polyclonal anti-Cbln1 (ab92526, Abcam) or 1:2,000 affinity-purified rabbit anti-
cerebellin-short antisera in 0.3 % Triton X-100 PBS with 2 % normal goat serum or 2 
% normal donkey serum for 48 h at 4 °C. The AVP and the VIP regions of the SCN 
were immunostained with guinea pig anti-AVP (T-5048, Peninsula Laboratories 
International) and guinea pig anti-VIP (T-5030, Peninsula Laboratories International) 
at 1:1,000 dilutions. Purkinje cells in the cerebellum were identified with mouse anti-
calbindin D-28K (C9848, Sigma-Aldrich) at 1:1,000 dilution. Lysosomes were 
identified with mouse anti-cathepsin D (ab6313, Abcam) at 1:500 dilution. After 
primary antibody incubation, slices were washed 3 x 10 min with PBS at room 
temperature. Slices were then incubated with the appropriate goat or donkey secondary 
antibodies conjugated to Alexa flour 488, 568, or 633 (Invitrogen) at 1:1,000 dilutions 
in 0.3% Triton-X 100 with 2% normal goat or donkey serum at room temperature for 1 
h. Nuclei were counter staining with DAPI (Thermo Fisher). Slices were mounted on 
gelatin-coated Superfrost microscope slides and coverslipped with Prolong Gold 





Confocal immunofluorescence images were captured on the LSM-710 confocal 
microscope (Zeiss). Image acquisition parameters (gain, offset, aperture, scan 
properties and laser power) were optimized for each objective and kept constant across 
repeated samples. Captured images were compiled in Zen2 and Adobe Photoshop CC 
with minimum alteration.  
 
Cell counting 
Z-stack images of the SCN were captured with 20x objective at 1 μm z-intervals. Raw 
images were divided with 8x8 grids and counted manually. SCN from at least 3 
animals with at least 3 slices per animal were counted.  
 
Synaptosomal fractionation and Western blot 
Synaptosomal fractionation protocol was based on previous publication [38]. Briefly, 
tissues in 9 volumes of the homogenizing buffer were homogenized with 4 strokes by 
a plastic pestle in 1.5 ml tubes on ice. The homogenate was centrifuged at 700 x g for 
10 min at 4 °C to pellet the nuclei/cell debris (P1) and the supernatant was collected 
(S1, post nuclear fraction). The S1 fraction was further centrifuged at 11,000 x g for 15 
min at 4 °C to separate the cytosol and light membrane supernatant fraction (S2) from 
the crude synaptosomal pellet fraction (P2). The P2 fraction containing crude 
synaptosomes was washed with the homogenizing buffer twice and lysed in RIPA 
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buffer containing protease inhibitors. At this point protein concentrations of the S2 and 
the P2 fractions were assessed with a BCA kit (Thermo Fisher). 
 
For Western blot analysis, S2 or P2 fractions containing 10 μg of protein were mixed 
with 5x loading buffer containing sodium dodecyl sulfate (SDS) and beta 
mercaptoethanol and denatured at 60 °C for 10 min. Denatured samples were resolved 
on 4 – 20% SDS-PAGE (Bio-Rad) and transferred to polyvinvldifluoride (PVDF) 
membrane (Millipore). Cbln1 and cleavage products were detected with either 1:1,000 
dilution of rabbit polyclonal anti-precerebellin antibody (PA5-20159, Thermo Fisher) 
or 1:1,000 affinity-purified rabbit anti-cerebellin-short antisera, followed by 1:2,500 
dilution of HRP-conjugated goat anti-rabbit antibody and visualized with SuperSignal 
Femto Maximum Sensitivity Substrate (Thermo Fisher). The membrane was then 
subjected to 1:10,000 dilution of rabbit anti-GAPDH antibody (G-9545, Sigma-
Aldrich), followed by 1:2,500 HRP-conjugated goat anti-rabbit antibody and 




Unpaired two-tailed student’s t-test was used to compare between the band intensities 
and the ratios for the synaptosomal fractionation experiments using the GraphPad 




Cerebellin-short and Cbln1 immunoreactivities localize differently in the rat 
cerebellum 
Previous studies reported different localizations of cerebellin-short and Cbln1 
immunoreactivities (IR) in the cerebellum. To confirm the specificity of the cerebellin-
short and the Cbln1 antibodies used for this investigation, immunofluorescence was 
performed in the rat cerebellum. Cerebellin-short IR were punctate and mainly 
localized between the Purkinje cell bodies in the Purkinje cell layer (Fig. 3.1A-D). 
Cbln1 IR on the other hand were localized to the molecular layer and concentrated 
around the dendritic trees of the Purkinje cells (Fig. 3.1E-H). These results agreed with 
previous publications [37,40] and suggested that the antibodies are specific to their 
respective targets.  
 
Cerebellin-short immunoreactivities co-localize with AVP- and VIP- positive cells 
in the SCN 
To examine possible region-specific localizations of the cerebellin-short peptide in the 
rat SCN, brain slices collected at ZT 8 were stained for both cerebellin-short and either 
AVP or VIP. AVP staining defined the dorsomedial region, while VIP staining marked 
the ventrolateral region of the SCN (Fig. 3.2B, 3.2F). Cerebellin-short IR appeared to 
be punctate around the cell bodies, and showed substantial overlap with both the AVP 
and the VIP cells (Fig. 3.2D & 3.2H). Cerebellin-short IR in the cell bodies appeared 
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stronger immediately outside of the SCN (Fig. 3.2A & 3.2E). Of all the counted AVP 
and VIP positive cells in the SCN, approximately 80% of the AVP- and VIP-positive 
cells were also positive for cerebellin-short IR. The percentages of AVP and VIP cells 
positive for cerebellin-short IR were not significantly different (data not shown).    
 
Cbln1 immunoreactivities localized immediately dorsal to the SCN and is widely 
present in the hypothalamus 
To examine the potential difference in localization between cerebellin-short and its 
precursor Cbln1, brain slices collected at ZT 8 were stained for Cbln1 alone with AVP 
to mark the SCN. Interesting, the strongest Cbln1 IR were immediately dorsal to the 
SCN along the 3rd ventricle, with patterns that resemble neuronal fibers (Fig. 3.3). The 
fibrous IR showed minimal overlap with the SCN and mostly terminated at the 
boundary of the dorsal medial SCN marked by both DAPI and AVP. Some AVP 
positive fibers extending from the SCN were also positive for Cbln1 IR, suggesting the 
presence of Cbln1 in these AVP cells.  
 
Outside of the SCN, intense Cbln1 IR were observed in other hypothalamic nuclei 
including the paraventricular nucleus (PVN) (Fig 3.4A), the median eminence (ME) 
(Fig. 3.4B), and the supraoptic nucleus (SON) (Fig. 3.4C-F). Cbln1 IR were also 
prominent along the axonal tracks that project from the PVN and the SON towards the 
posterior pituitary. In the SON, Cbln1 IR (Fig. 3.4C) and AVP (Fig. 3.4D) showed no 
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co-localization, indicating the absence of Cbln1 in the AVP magnocellular neurons of 
the SON.   
 
Both cerebellin-short and Cbln1 immunoreactivities do not co-localize with 
GFAP-positive astrocytes in the mouse SCN 
To determine whether Cbln1 and cerebellin-short in the SCN are also present in glial 
cells, immunofluorescence was performed on the transgenic Brainbow GFAP-Cre 
mouse line that stochastically expresses fluorescent proteins in GFAP-positive cells. 
Upon SCN staining, both the cerebellin-short and Cbln1 IR showed no co-localization 
with GFAP-induced Brainbow fluorescence in the mice SCN (Fig. 3.5).  
 
The 15 kDa cleavage product of Cbln1 is enriched in the crude synaptosomal 
fraction in both the SCN and the cerebellum 
Cbln1 undergoes extensive processing to yield cerebellin peptides. One of the 
processing intermediate is the 15 kDa cleavage product discussed in the previous 
chapter formed by the cleavage of Cbln1 at the N-terminus of the cerebellin sequence. 
The 15 kDa cleavage product is recognized by the cerebellin-short antisera on Western 
blot, whereas the ~1.4 kDa cerebellin peptides were not observed possibly due to their 
low molecular weight and the detection limit of the Western blot technique. To 
examine the processing of Cbln1 in the SCN, SCN tissue was subjected to 
synaptosomal fractionation by centrifugation followed by electrophoresis on SDS-
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PAGE and detection by Western blot. Both Cbln1 and the 15 kDa cleavage product 
were present in the cytosol and light membrane fraction (S2), but the 15 kDa cleavage 
product was enriched in the crude synaptosome fraction (P2) of the SCN with minimal 
amounts of Cbln1 observed (Fig.3.6A). A similar pattern was also observed in the 
cerebellum, although slightly higher amounts of Cbln1 was observed in the P2 fraction 
compared to the SCN (Fig. 3.6A). These results were initially puzzling, as Cbln1 was 
observed in the SCN S2 fraction but Cbln1 IR were minimal in the SCN. One possible 
explanation is that during tissue acquisition Cbln1 in neuronal processes dorsal to the 
SCN (Fig. 3.3A) were inevitably collected due the size of the biopsy punch.  
 
In the S2 fraction of the SCN, the amount of Cbln1 was generally higher than the 15 
kDa cleavage product when normalized to GAPDH, although the difference was not 
statistically significant (Fig. 3.6B) (Unpaired t-test, P-value = 0.194). In the P2 
fraction, the opposite trend was observed (Fig. 3.6C) (Unpaired t-test, P-value = 
0.0551). When the 15 kDa cleavage product to Cbln1 ratio was compared between the 
SCN S2 and the P2 fractions, the P2 fraction had significant enrichment of the 15 kDa 
cleavage product compared to the S2 fraction (Fig. 3.6D) (Unpaired t-test, P-value = 
0.0137). In the S2 fraction of the cerebellum, the amount of Cbln1 was significantly 
higher than the 15 kDa cleavage product when normalized to GAPDH (Fig. 3.6E) 
(Unpaired t-test, P-value = 0.0025). In the P2 fraction, the 15 kDa cleavage product 
was significantly higher than Cbln1 (Fig. 3.6F) (Unpaired t-test, P-value = 0.0047). 
The ratio of 15 kDa cleavage product to Cbln1 in the cerebellum was also significantly 
53 
 
higher in the P2 fraction compared to the S2 fraction (Fig. 3.6G) (Unpaired t-test, P-
value = 0.0032).   
 
3.5 DISCUSSION 
Cerebellin-short IR showed high overlap with both AVP and VIP cells in the SCN 
Cerebellin-short IR were predominantly punctate in the neuronal cell bodies, with 
some puncta localized to the lysosomes as previously reported (data not shown) 
[35,37]. Localization to the lysosomes indicates the possibility of active degradation. 
Transfer of Cbln1 from presynaptic granule cells to postsynaptic Purkinje cells and 
Bergmann glia were previously described in the cerebellum [37]. Secreted Cbln1 at the 
synapse were speculated to be internalized through the endosomal pathway, some of 
which may be shuttled to the lysosomes for degradation [37]. Lysosomes might also 
process Cbln1 into cerebellin peptides for alternative functions in the cerebellum yet to 
be discovered. In the SCN the same mechanism might be in place to impose circadian 
modulation on the level of available cerebellin-short peptides. Alternatively, 
localization of cerebellin-short IR to the lysosomes might be a part of a secretion 
mechanism involving the fusion of lysosomes to the plasma membrane [41,42]. 
 
When the entire SCN was analyzed, cerebellin-short IR did not localize exclusively to 
either the dorsomedial or the ventrolateral SCN designated by AVP and VIP. Instead, 
around 80% of both AVP and VIP cells in the SCN were positive for cerebellin-short 
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IR. This result suggests that cerebellin-short is widely present throughout the SCN and 
might functionally connect the two regions critical to circadian time keeping.  
 
Cbln1 IR is prevalent in the hypothalamus and distinct from cerebellin-short IR 
in the SCN 
In contrast to the cerebellin-short IR, Cbln1 IR were minimal in the SCN but were 
prominent in processes immediately dorsal to the SCN along the 3rd ventricle. SCN is 
known to project directly to the PVN and the sub-paraventricular area [43], suggesting 
the possibility of Cbln1 transport between the SCN and the PVN. This speculation is 
supported by the observation of high amounts of Cbln1 IR in the PVN magnocellular 
neuron cell bodies and axons. Magnocellular neurons from the PVN project to the 
posterior pituitary through the hypothalamo-neurohypophysial system, where peptides 
and hormonal signals are released into the bloodstream [44,45]. Previous study also 
reported presence of Cbln1 in the posterior pituitary [46,47]. One possibility is that 
Cbln1 from the SCN is transported to the PVN and the posterior pituitary for functions 
distinct from the circadian modulation conferred by cerebellin-short in the SCN 
discussed in the previous chapter. Alternatively, Cbln1 is transported from the PVN to 
the SCN, which is then processed into cerebellin-short to modulate circadian rhythm.  
 
Cbln1 IR were also observed in the SON magnocellular neurons and were distinct 
from the AVP cells. Like the PVN, magnocellular neurons from the SON also project 
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axons to the posterior pituitary [44,45]. Synthetic cerebellin peptide was known to 
stimulate the release of norepinephrine from rat adrenal glands [48,49], suggesting the 
involvement of Cbln1 in the hypothalamic-pituitary-adrenal axis.  
Cbln1 and cerebellin-short are neuronal in the SCN 
Astrocytes in the SCN are an integral part in facilitating circadian rhythm [50–52]. As 
mentioned previously, Cbln1 can be transferred from the granule cells to the 
Bergmann glia in the cerebellum. This observation raised the question whether Cbln1 
and cerebellin-short in the SCN could also be present in astrocytes. Upon staining in 
GFAP-Cre Astrobow mice, cerebellin-short IR co-localized with GFAP-positive 
Bergmann glia in the cerebellum (data not shown), confirming previously published 
results. In contrast, neither Cbln1 nor cerebellin-short IR were observed in SCN 
GFAP-positive astrocytes, suggesting their neuronal origins. 
  
Processing of Cbln1 into cerebellin peptides takes place at the synapse or 
lysosomes 
Cbln1 undergo extensive processing through multiple intermediates to yield the 
cerebellin peptides [38]. At the N-terminus of the cerebellin sequence in Cbln1, a 
cleavage site similar to that in proTNα is present [38,53]. ProTNFα is cleaved by the 
TACE metalloprotease to release TNFα, suggesting the possibility that TACE could 
also cleave Cbln1. At the C-terminus of the cerebellin sequence endopeptidase 
possibly responsible for the cleavage has yet to be identified. The 15 kDa cleavage 
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product observed in this investigation most likely corresponded to the C-terminal 
product when Cbln1 is cleaved at the N-terminus of the cerebellin sequence. This 
cleavage was previously reported to be common and happened spontaneously when 
recombinant Cbln1 was being prepared for crystallography structural studies [54]. 
Beyond these observations, the exact steps and enzymes involved in the complete 
processing of Cbln1 into cerebellin peptides remain largely a mystery. 
 
Cerebellin peptides was previously described to be enriched in the crude synaptosomal 
fraction of the cerebellum when examined with HPLC [55]. This observation agrees 
with the result of this investigation, as the 15 kDa processing intermediate was 
enriched in the crude synaptosomal fraction of the cerebellum and the SCN. Crude 
synaptosomal enrichments of the 15 kDa cleavage product in both the cerebellum and 
the SCN suggest that subsequent cleavages of Cbln1 at the C-terminus of the 
cerebellin sequence to produce cerebellin peptides take place at the synapse. The 
diminished amounts of Cbln1 in the P2 fractions suggest that Cbln1 levels are low in 
the synapse relative to cerebellin peptides, perhaps due to rapid secretion or turnover. 
15 kDa cleavage product could also be in other membrane-bound vesicles of similar 
densities to synaptosomes. Electron microscopy study showed that lysosomes are 
sometimes observed in crude synaptosomal preparations due to their similar densities 
with synaptosomes [56]. As discussed earlier, lysosomes possibly modulate the level 
of Cbln1 through degradation/cleavage. This mechanism can simultaneously produce 
cerebellin peptides, providing a possible control mechanism for the functionally 
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distinct yet intertwined Cbln1 and cerebellin peptide. The question remains whether 
Cbln1 is secreted in the SCN and functionally participates in either synapse formation 
or circadian time keeping.  
  
Data presented in this investigation suggest active processing of Cbln1 into cerebellin 
peptides in both the AVP and VIP regions of the SCN. Processing of Cbln1 into 
cerebellin peptides in the SCN happens at either or both the synapse and the 
lysosomes. Outside of the SCN, Cbln1 is observed in the PVN and the SON and 
possibly confer functions in the hypothalamic-pituitary-adrenal axis distinct from the 







Figure 3.1. Cerebellin-short and Cbln1 IR show different localization in the rat 
Cerebellum. (A) Confocal images of ZT 8 cerebellum immunostained with anti-
cerebellin-short (A) or anti-Cbln1 (E) (red), anti-calbindin D-28K (B and F) (green), 
and DAPI (C and G) (blue). When merged, anti-cerebellin short IR localized in puncta 
at the Purkinje cell layer around the cell bodies or Purkinje cells and Bergmann glia 
(D). Anti-Cbln1 on the other hand were localized along the Purkinje cell dendritic 
trees (H). 2x2 tile scanned with 40x objective (A-D). Single 40x image (E-H). Scale 
bar: 50 μm (A-D), 20 μm (E-H). ML: Molecular layer, PL: Purkinje cell layer: GL: 
Granule cell layer. 
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Figure 3.1 (cont.). Cerebellin-short and Cbln1 IR show different localization in 






Figure 3.2. Cerebellin-short IR co-localize with both AVP and VIP positive cells 
in the rat SCN. 2x2 tile scanned 40x confocal images of ZT 8 medial SCN 
immunostained with anti-cerebellin-short (A and E) (red), anti-AVP (B) or anti-VIP 
(F) (green), and DAPI (C and G). When merged, anti-cerebellin-short IR showed 
punctate staining in the cell bodies of both AVP and VIP positive cells (D and H). 
Scale bar: 50 μm. White dotted lines outline the SCN based on DAPI.  
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Figure 3.2 (cont.). Cerebellin-short IR co-localize with both AVP and VIP positive 
cells in the rat SCN. 
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Figure 3.3. Cbln1 IR are fibrous and immediately dorsal to the SCN. 2x2 tile 
scanned 40x confocal images of ZT 8 medial SCN immunostained with anti-Cbln1 (A) 
(red), anti-AVP (B) (green), and DAPI (C) (blue). When merged, Cbln1 IR appeared 
fibrous immediately dorsal to the SCN along the 3rd ventricle. Minimal Cbln1 IR was 
observed within the SCN (D). White dotted lines outline the SCN based on DAPI. 

















































































































































































































































































































































































































Figure 3.4 (cont.). Cbln1 IR are present in multiple rat hypothalamic nuclei and 
neuronal processes. The SON was immunostained with anti-Cbln1(C) (red), anti-
AVP (D) (green) and DAPI (E) (blue). When combined, Cbln1 IR localized to 
magnocellular neurons and their processes distinct from those positive for AVP (F). 









Figure 3.5. Both cerebellin-short and Cbln1 IR do not co-localize with GFAP-
expressing astrocytes in the mouse SCN. 2x2 tile scanned 40x confocal images of 
ZT 8 medial SCN of transgenic GFAP-Cre Brainbow mice immunostained with anti-
cerebellin-short (A) or anti-Cbln1 (D) (Alexa 633 pseudo-colored red). Fluorescent 
signals from YFP and RFP captured through different channels were combined and 
pseudo-colored green for the ease of viewing (B and E). When combined, both anti-
cerebellin-short and Cbln1 IR showed punctate staining in the cell bodies, which did 
not co-localize with GFAP-expressing astrocytes in the mouse SCN (C and F). Scale 











Figure 3.5 (cont.). Both cerebellin-short and Cbln1 IR do not co-localize with 
GFAP-expressing astrocytes in the mouse SCN. Zoomed in images showing no 
overlap between either cerebellin-short or Cbln1 IR with astrocyte fluorescence (Ci 










Figure 3.6. The 15 kDa cleavage product of Cbln1 is enriched in the crude 
synaptosomal fractions of both the SCN and the cerebellum. (A) The cytosol light 
membrane fractions (S2) and the crude synaptosome fractions (P2) from ZT 8 SCN 
and cerebellum were immunoblotted with anti-Cbln1 and anti-cerebellin-short. Anti-
Cbln1 detected a single band ~25 kDa, corresponding to Cbln1. Anti-cerebellin-short 
detected a single band ~15 kDa, corresponding to the C-terminal portion of Cbln1 
cleaved at the N-terminus of the cerebellin sequence. Cbln1 was high in the S2 
fractions of both the SCN and the cerebellum, but the amount diminished in the P2 
fractions. 15 kDa cleavage product were low in the S2 fractions in both the SCN and 
the cerebellum, but enriched in P2 fractions from both regions compared to Cbln1. 












Figure 3.6 (cont.). The 15 kDa cleavage product of Cbln1 is enriched in the crude 
synaptosomal fractions of both the SCN and the cerebellum. The intensities of 
Cbln1 and 15 kDa cleavage products in the S2 and the P2 fractions from both brain 
regions were compared separately after normalizing to GAPDH (B, C, E and F). The 
ratios of band intensities of 15 kDa cleavage product to Cbln1 were also compared 
between the S2 and the P2 fractions in both brain regions (D and G). Results showed 
significant enrichment of the 15 kDa cleavage product in the P2 fractions from both 
brain regions. Graphs show mean ± SEM, unpaired two-tailed t-test, * P ≤ 0.05 ** P ≤ 
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CHAPTER FOUR: METABOLOMIC AND LIPIDOMIC 
CHANGES DURING LONG TERM POTENTIATION  REVEALED 
BY MASS SPECTROMETRY IMAGING IN THE MOUSE 
HIPPOCAMPUS1  
4.1 ABSTRACT 
Brain plasticity is well known as the underlying mechanism for memory encoding in 
the brain. Long term potentiation (LTP) is the best-studied tissue model for learning 
and memory, and tracking the chemical changes during LTP is critical for unveiling 
the mechanism of the process. However, due to the technical limitation, majority of the 
molecular studies of LTP focused on primary messengers and large proteins. On the 
other hand, signaling lipids and small signaling metabolites are less studied. In this 
work, we used dopamine (DA)-modified TiO2-assisted laser desorption/ionization 
(LDI)-mass spectrometry imaging (MSI) to spatially track the metabolomic and the 
lipidomic changes in the hippocampus after LTP induction in the Schaffer collateral-
CA1 pathway. In the CA1 region we observed the increase of creatine, spermine, and 
                                                          
1 This work was done in collaboration with Qian Wu Ph.D. from the lab of Prof. Jonathan Sweedler of 
analytical chemistry at the University of Illinois at Urbana-Champaign. This work was supported by the 
Center for Nutrition, Learning and Memory (CNLM) with funding from Abbott’s Nutrition Business. 
Qian Wu assembled the initial manuscript, and James Chu edited the manuscript extensively in 
preparation for submission for publication. James Chu performed the LTP recordings and analyzed the 
electrophysiological data. Qian Wu performed the MSI experiments and analyzed analytical chemistry 
data. Ann Benefiel and Mia Yu Ph.D. provided animal care. Jennifer Mitchell Ph.D., Stas Rubakhin 
Ph.D., Prof. Martha Gillette and Prof. Jonathan Sweedler provided guidance for experiments and 
manuscript assembly.   
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two amino acids. In the CA2/3 region we observed the increase of ceramide, four fatty 
acids, three phosphatidylethanolamine (PE) and the decrease of creatinine and one 
phosphatidylcholine (PC).  These changes dominated the differences between LTP 
versus control hippocampal slices from mice 8 month in age. The magnitude of 
chemical changes is correlated to the magnitude of LTP-induction. Majority of the 
observed chemical changes agree with previously reported LTP signaling pathways or 
the related pathways downstream of Ca2+ flux. Creatinine/creatine changes can be 
attributed to energy shuttling, fatty acids/PC/PE changes fall under polyunsaturated 
fatty acids (PUFA) signaling, ceramides and cholesterol are related to lipid rafts, 
GABA change is related to neurotransmission, and spermine change is related to 
NMDA receptor activation. We demonstrate the first use of MSI to simultaneously 
visualize multiple previous reported LTP chemical changes. In addition, we observed 
cholesterol changes that cannot be explained by known pathways and pyroglutamate 
changes not previously reported. These results provided important new information for 
the molecular substrates of brain plasticity. 
 
4.2 INTRODUCTION 
The brain can adapt to the environment by forming new connections or changing the 
strength of existing connections between neurons. This process is known as brain 
plasticity [1]. Brain plasticity is widely assumed to be the mechanism by which 
memory is encoded and stored in the central nervous system. Long term potentiation 
(LTP) is the best studied brain plasticity mechanism [2], in which synaptic potentials, 
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evoked by low-frequency stimulation, are observed to increase in amplitude as a 
consequence of a brief pulse of high-frequency stimulation or the pairing of 
presynaptic activity with postsynaptic depolarization. To this day, LTP remains the 
most widely used model for the study of learning and memory in vertebrates [3]. 
 
The molecular mechanism of LTP is well dissected in the past decades, with efforts 
largely focused on small primary messengers such as neurotransmitters and large 
proteins such as enzymes and receptors [4]. However, lipids which makes up more 
than half of the human brain in dry weight received much less attention. Recent 
advances in cell biology, synaptic physiology and receptor pharmacology lead to the 
discoveries that lipids have broad information carrying roles in the CNS, including 
altering the geometric properties and supramolecular organization of neuronal/glial 
membranes and taking role as ligands for proteins, secondary messenger or precursor 
of other signaling molecules [5,6]. For example, the dissociations of phospholipids 
into cone-shaped fatty acids and lysophospholipids at cell membrane have important 
roles in synaptic vesicle exocytosis [7]. The dissociation of PC can generate platelet-
activating factor which is a retrograde messenger that activates the presynaptic 
mechanisms facilitating synaptic plasticity during LTP [8]. PUFA such as DHA and 





To understand the chemical mechanism of lipids and lipid derivatives during memory 
and learning, imaging techniques that track lipidomic changes during plasticity are 
critical. However, imaging of lipidomic changes during brain plasticity are scarce; 
most imaging techniques used to study LTP are specific for small metabolites or larger 
proteins. Optical imaging with voltage-sensitive dyes are used to visualize neurons [9] 
and Ca2+ sensitive dyes are used to capture Ca2+ fluxes [10]. Fluorescent molecules are 
used to track small signaling molecule such as NO [11], glutamate [12] and even 
cholesterol [13], while magnetic resonance spectroscopy (MRS) is used for imaging 
small metabolites [14]. These methods have been widely employed to track specific 
signaling molecules for brain or neuronal plasticity. Optical imaging methods have 
high spatial resolution that allow tracking of target molecules at the synaptic scale, but 
the number of different molecules that can be simultaneously monitored is limited. 
MRS imaging is capable of in vivo measurements, but suffers from low sensitivity and 
limited resolution.  
 
Mass spectrometry imaging (MSI) is a sensitive and multiplexed approach for the 
characterization and localization of a wide range of analytes including small 
metabolites [15,16], lipids [17], peptides and proteins [18]. The wide analyte spectrum 
makes MSI an attractive method to simultaneously visualize all the important 
compounds and identify key signaling substrates. Time-of-flight secondary-ion mass 
spectrometry has previously been used to produce high-resolution images of the 
microscopic changes in lipid composition that occur at the fusion sites between two 
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mating cells of the protozoon Tetrahymena thermophile [7]. Indeed, the goal of 
profiling large-scale changes in lipid composition or determining the topographical 
distribution of individual lipid species is no longer beyond reach after the advancement 
of the MSI technology.  
 
Recently, we developed a new surface-assisted laser desorption/ionization (MALDI)-
MSI method with dopamine (DA)-modified TiO2 monolith. With this improved 
method, small amino acids, alkaloids, fatty acids together with larger lipids including 
diglycerides, ceramides, PE and PC can be localized simultaneously in brain tissues in 
high spatial resolution up to 20 µm [19]. In this work, this unique MSI method was 
used to track the lipidomics and metabolomics changes associated with the LTP 
formation, and to identify the most important signaling molecules dominating the 
changes among the compounds we can detected with this method. Most of the 
observed changes in chemical compounds agree with reported LTP signaling 
pathways. In addition, we observed changes in several compounds that were not 
previously reported. Thus, our results provide a basic chemical information list for 







4.3 MATERIALS AND METHODS 
Chemicals and materials 
The following chemicals were purchased from Sigma-Aldrich (St. Louis, MO): n-
methyl-D-glucamine, potassium chloride, sodium phosphate monobasic, (+)-sodium 
L-ascorbate, thiourea, sodium pyruvate, magnesium sulfate anhydrous, picrotoxin, 
titanium (IV) n-butoxide, dopamine hydrochloride (>98%). Concentrated phosphoric 
acid (analytical grade), sodium bicarbonate, HEPES, calcium chloride, D-glucose, 
sodium chloride, acetonitrile, ethanol, and water (liquid chromatography (LC)/MS 
grade) were purchased from Fisher Scientific (Pittsburgh, PA). 
 
Animal experiments 
Inbred C57BL/6 mice of both genders around the age of 8 months were used. Animals 
were housed under 12h:12h light-dark cycle at 18–26 °C, 30–70% humidity. Food and 
water were accessible ab libitum. All animal-related procedures, including euthanasia 
by cervical dislocation, were performed in compliance with local and federal 
regulations and according to animal use protocols approved by the University of 







Mouse was cervically dislocated, decapitated and the brain quickly extracted. The 
brain was chilled in NMDG-artificial cerebral spinal fluid (ACSF) slicing solution at 
4 °C containing (in mM) NMDG 93, KCl 2.5, NAH2PO4, 1.2, NaHCO3 30, HEPES 20, 
glucose 25, sodium ascorbate 5, thiourea 2, sodium pyruvate 3, MgSO4 10 and CaCl2 
0.5, bubbled continuously with 95% O2/ 5% CO2 [20]. Coronal hippocampal slices, 
400 µm thick, were obtained with a Leica vibratome.  
 
After slicing, slices were allowed to recover for 10 min in NMDG-ACSF at 30 °C, 
then transferred to a submerged recording chamber perfused with ACSF solution (2 
ml/min) containing (in mM) NaCl 124, KCl 2.5, NaH2PO4 1.2, NaHCO3 24, HEPES 5, 
glucose 12.5, MgSO4 2, CaCl2 2 and Picrotoxin 50, bubbled continuously with 95% 
O2/ 5% CO2 at 30 °C. Slices were equilibrated in the recording chamber for 1 h before 
LTP recording.  
 
Stimulations were performed with a concentric bipolar electrode (FHC) placed at the 
Schaffer collateral between CA3 and CA1, recordings were performed with a tungsten 
electrode (FHC) placed at the striatum radiatum of CA1. Field excitatory postsynaptic 
potential (fEPSP) was monitored until stable and input-output curves were obtained. 
Slices were given test-pulses (0.033 Hz) at ~ 40% maximum fEPSP throughout the 
recording. After a minimum of 20 min stable baseline recording, LTP was induced by 
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3 trains of 100 Hz, 1000 ms duration, 15 s interval high frequency stimulations (HFS) 
at test-pulse strength. For signal acquisition, amplifier gain was set to 1000 and filtered 
between 1 Hz to 3 kHz. Signals were recorded and processed with pClamp 10 
software. To control for the effect of electrode insertions and electrical stimulations on 
MSI, control slices were generated from the same brains and only subjected to test-
pulses without LTP induction. After recording, brain slices were transferred to glass 
slides covered with Parafilm and flash frozen over dry ice for further cryo-sectioning 
and MSI. 
 
Synthesis of TiO2 monolith 
TiO2 nanoparticles were prepared using a previously described sol-gel method to 
hydrolyze titanium(IV) n-butoxide in an ethanol-water solution under acidic condition 
[21]. Briefly, 3.4 mL of titanium (IV) n-butoxide and 1.6 mL of ethanol were mixed by 
vortex for 1 min, forming a precursor solution. Then, a solution containing 5 mL of 
ethanol with 0.1 M nitric acid and 1% HPLC grade water was added dropwise to the 
vigorously stirred precursor solution, which was cooled in an ice/water bath. TiO2 
structures were formed in this solution (Solution I) during stirring in an ice/water bath 
for 3 h. To prepare DA-modified TiO2 monolith deposition mixture, 250 µL of 
solution I was diluted in 5 mL of reaction solution (solution II) for further 
hydrolysis/condensation. Solution II consists of 5% water-ethanol solution with 0.005 
M DA. The mixture of solution I and solution II was incubated for 1 h. 
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Sample preparation for MSI  
The 400 µm thick frozen coronal brain slices were further cryo-sectioned into sets of 
10-µm thick sections using a cryostat (Leica CM3050 S, Leica Biosystems Inc.). 
Slices with LTP-induction (or pulse test) and the corresponding control slices were 
paired tightly, thaw-mounted on indium-tin-oxide coated glass slides (Delta 
Technology Ltd., Loveland, CO) and dried in an N2-filled desiccator for 20 min.  
 
For TiO2-assisted LDI, DA-modified TiO2 monolith deposition mixture were applied 
to tissue sections by airbrush-assisted deposition. Briefly, 5 mL of the above described, 
appropriately diluted TiO2-containing solution were sprayed with a 0.2 mm nozzle 
airbrush (Paasche Airbrush Company, Chicago, IL), with a nozzle-to-target distance of 
~50 cm and nozzle nitrogen gas pressure at 35 psi. The final TiO2 material layer was 
~400 µg/cm2, determined by comparing sample weight before and after sublimation. 
 
Sample preparation for LC-MS/MS 
10-µm thick sections on glass slide are scratched out with needle under microscope 
according to anatomical morphology. CA1 and CA3 regions of each animal were 
collected and extracted with 400 µL methanol-chloroform (2:3) solution under 
sonication on ice in a bath sonicator (8891 Ultrasonic Cleaner, Cole-Parmer, Vernon 
Hills, IL) for 10 min. The extracts were centrifuged at 6,600 ×g at 4 ⁰C for 5 min and 
the supernatants collected (extraction solution I). After centrifugation, the pallets were 
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extracted with 50 µL methanol-water again under sonication, and the extracts were 
centrifuged at 6,600 ×g at 4 ⁰C for 5 min. The supernatant (extraction solution II) was 
collected for direct injection into LC-MS/MS to detect creatinine. Extraction solution I 
was divided into two parts. The first part was dried with a gentle N2 stream at ambient 
conditions, re-dissolved into 50 µL methanol, and directly injected into LC-MS/MS 
for to detect cholesterol. The other part was dried with a gentle N2 stream at ambient 
conditions, derivatized, and injected into the LC system to validate the MALDI results. 
 
MS analyses 
MALDI time-of-flight (TOF)/TOF MSI was performed using an ultrafleXtreme II 
mass spectrometer (Bruker Daltonics, Billerica, MA) equipped with a solid-state UV 
Smartbeam II laser. Tandem MS (MS/MS) analysis was used to elucidate the structural 
properties of the detected compounds. MS/MS was carried out in the LIFT mode 
utilizing argon as a collision gas at a 2 Da precursor isolation window. 
 
Equipped with a MALDI ion source, a solariX™ XR Fourier transform ion cyclotron 
resonance (FTICR) mass spectrometer (Bruker Daltonics) was used for high mass 





Data processing and statistical analysis 
The molecular ion distribution images of tissue sections were visualized using 
flexImaging. Different cell layers in different regions were manually defined according 
to anatomical morphologies in optical images and ion images, and the spectra in 
regions of interest (ROI) were exported, imported into ClinProTools (Bruker) with 
automatic baseline subtraction and total ion count normalization. Peaks were picked 
with a signal/noise threshold greater than 3 on average spectra and matrix-related 
peaks were removed. Picked peaks were exported as m/z value-peak intensity tables. 
For five repeated, combat method [22] was used for normalization to remove batch 
effect of different slides using online tool (metaboanalysis 3.0, 
http://www.metaboanalyst.ca/faces/Secure/utils/BatchUpload.xhtml).  
 
After normalization, data from five replicates were combined for multivariate analysis. 
Principal component analysis (PCA)) was done by OriginPro 8.5 (OriginLab 
Corporation, Northampton, MA), and Orthogonal partial least squares (OPLS) was 
done by SIMCA 14.1.  For comparison of averaged peak intensities of signals acquired 
from different brain regions, a two sample t-test was calculated using OriginPro 8.5 to 
determine significant differences between the average peak intensities of each pair of 






LTP induction/recording and MS imaging for tracking small metabolites and 
lipids changes in hippocampus  
We previously demonstrated that TiO2-DA-assisted LDI has higher selectivity and 
sensitivity for Lewis basic lipids, such as fatty acids, cholesterols, ceramides, DAGs 
and PEs, in positive mode [19]. In the given mice hippocampus tissue, 35 small 
molecules (including amino acids, alkaloids, free fatty acids and dipeptides) and over 
50 lipids (including cholesterols, ceramides, diacylglycerol (DAG), GlcCer, 
phosphatidic acid (PA), PE-Cer, PCs and PEs) were detected with TiO2-DA monolith-
assisted LDI MSI and identified with FTICR MS and MALDI MS/MS. 
 
Schaffer collateral axons running from CA3 to CA1 were used for field stimulation, 
and the stimulating electrode was placed near the sr of CA2 where most of Schaffer 
collateral axons are present (Fig. 4.1A). fEPSP was recorded near the sr and the slm of 
CA1, which contain most of the Schaffer collateral axonal terminals that synapse onto 
the CA1 pyramidal cells dendrites. A sample recording correlating time to mean 
percentage (%) fEPSP slope to baseline before and after LTP induction is shown in 
Figure 5.1B. 
 
To detect the spatio-chemical changes of the hippocampus after LTP induction, mouse 
brain was sectioned and divided into two sides. One side was used for  
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LTP induction, while the other side was used as untouched control incubated in the 
same condition as the LTP side (two sides are selected randomly every time). Slices 
were frozen immediately after LTP recording, and further sectioned into 10-um slices 
for TiO2-DA-assisted LDI MSI (Fig. 4.1C). This procedure identifies compounds 
involved in LTP formation. To distinguish the changes induced by HFS LTP induction 
versus test pulses, separate control slices exposed to test pulses only were prepared and 
compared to untouched controls. 
 
Though symmetric contralateral hippocampal slices were used for experiment and 
control, different matrix effects, such as salt content and surface properties, can also 
contribute to artifacts in MSI signal. Thus, to demonstrate that the detected signals 
indeed correspond to changes in compound levels, we used LC-MS/MS to validate 
MSI results for several important biomarkers. All detected compounds have 
correlation coefficient > 0.9 except for cholesterol. Low correlation of cholesterol may 
be due to its high concentration in the fiber tracts, which potentially contaminated the 
hippocampal tissue when tissue scratching was done for LC-MS/MS.  
 
Untargeted analysis of chemical changes after LTP  
We used multivariate analysis to find spatio-chemical changes in metabolites and 
lipids of the hippocampus after LTP induction. MSI data in hippocampus was 
separated into so, sp, sr and slm cell layers of CA1, CA2 and CA3 sub regions 
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according to anatomical morphology in optical images as well as ion images of some 
representative compounds. Mass spectra from different selected layers were exported 
and analyzed with PCA, a complementary multivariate analysis technique.  
 
Score plot of PCA shows that the CA2 and the CA3 regions have the most separation 
between control (black dots) and LTP sample (red dots) (Figure 4.2A). For the CA1 
region, control and LTP sample cannot be separated in most of the layers except for 
the so layer. In the CA1 so layer, two samples can be separated in the PC1 axis. For 
the CA2 regions, samples can be separated in all the layers in the PC3 axis.  For the 
CA3 region, only the slm layer have obvious separation of two sample dots in the PC3 
axis. It can be seen that the CA2 region, where the stimulating electrode is placed, had 
the most obvious separation. The slm and sr layers containing most of the Schaffer 
collateral axons have the largest separations in both the CA2 and the CA3, so the 
changes from PCA correspond to the position where LTP occurred. However, when 
the PCA score plots of untouched control sample were compared to test pulse control 
samples, no obvious separation is observed, except the sp and sr of the CA3 in the PC3 
axis.  
 
To investigate specific changes of multiple compounds and identify compounds that 
changed significantly in different layers, OPLS as a supervised untargeted analysis 
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method was used. S-plot was used to find the compounds dominating the changes 
found in different layers (figure 4.2B).  
 
S-plot indicates the difference of each compound in control versus LTP classes [23]. 
P[1] describes the magnitude of each compound change, and P(corr) represents the 
reliability of each compounds change. Thus, compound with high P[1] and P(corr) has 
a bigger influence on the separation of two classes, identifying the compound as the 
dominating  difference between control and LTP. In accordance to previously 
published studies [24], we set P[1] > 0.05 and P(corr) > 0.4 as threshold. Compounds 
matching this threshold in different layers are listed in Table 4.1.  
 
MS/MS spectra were obtained for these peaks to elucidate the precise structure 
including lipids side chains. Small alkaloids, amino acids and amino acid derivatives 
dominate the changes in the CA1. Changes in the CA2 and the CA3 are dominated by 
lipids such as phospholipids, ceramides, cholesterol and fatty acids.  
 
We also compared the control and test pulse control classes. In the sp and sr layer of 
the CA3, which had obvious separation in PCA score plot, was used to do OPLS. 
Resulting s-plots show that among compounds listed in Table 4.1 only 5-HT, 
pyroglutamate and creatine have p(corr) > 0.4. Changes of these compounds were not 
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in the CA3 region for the LTP samples according the s-plot. Thus, compound changes 
identified in LTP samples are due to LTP induction instead of the test pulse. 
 
Statistical analysis of biomarker changes after LTP induction  
Ion images of compounds changed significantly after LTP induction in multiple 
regions and layers (Fig. 4.3).  These include four alkaloids (creatine, creatinine, 5-
hydroxyltryptophol and spermine),  two amino acid derivatives (pyroglumtamic acid 
and GABA), four fatty acids (FA(20:4)/AA, FA(22:6)/DHA, FA(18:1) and FA (22:4)), 
one PC (PC(20:4/18:2)), three PEs (PE(20:4/20:3), PE(20:4/18:0) and PE(38:3)), 
cholesterol and one ceramide (Cer(d18:1/18:0)). The specific fold changes and p-
values are listed in Table 4.1. Most of the alkaloids and amino acid derivatives 
increased in the CA1 cell layers, and most of the fatty acids and lipids increased in the 
CA2 or the CA3 cell layers, except PC(20:4/18:2) which decreased in the CA3 cell 
layers. Most of the mentioned compounds have previously been reported to be 
implicated in LTP, synaptic plasticity or neurotransmission processes. Details of the 
compounds and their functions are discussed in later sections. 
 
For test pulse samples, the fold change and have no significant changes between 
control versus test pulse except for the increase of creatine in the sp and GABA in the 




Correlating the change ratios with fEPSP magnitude 
To investigate the correlation of the change ratios of above mentioned compounds 
with LTP magnitude, plot of change ratio versus corresponding LTP fEPSP of five 
replicate animals are constructed. All compounds investigated have linear correlation 
between change ratio and fEPSP magnitude, and all the correlation coefficients are 
higher than 0.75, with most near 0.9.  
 
4.5 DISCUSSION 
LTP process and its molecular mechanism 
LTP is the long-lasting increase of synaptic strength induced by high-frequency 
stimulation. This phenomenon is an evidence for synaptic plasticity, which was 
proposed to be a foundational element in learning and memory. To this day LTP is 
believed to be one of the primary mechanisms giving rise to synaptic plasticity in the 
brain and remains an uncontested cellular model of learning and memory.  
 
Elucidating the molecular mechanism of LTP is important for understanding learning 
and memory as well as treating neurodegenerative diseases. Majority of the published 
reports suggest the increase of synaptic strength following LTP is due to modification 




As shown in Figure 4.5, depolarization of the postsynapse cause by HFS will displace 
the Mg2+ blockade of the NMDA receptor channel and cause Ca2+ influx [27,28]. Ca2+ 
influx activates a collection of enzymes and initiate several second messenger 
signaling pathways that proceed to modify the postsynapse. Here MSI of both small 
metabolites and lipids was used for the first time to observe the spatio-chemical 
changes associated with LTP induction, which may provide more information about 
the secondary signaling process. From literatures and also the hierarchical clustering 
results (Fig. 4.4A), chemical changes can be separated into different groups, and each 
group has similar spatial distribution changes during LTP (Fig. 4.4B). Creatine and 
creatinine are grouped as important energy shuttle for storing phosphate group (Fig. 
4.5). Fatty acids and phospholipids are involved in hydrolysis reaction of 
phospholipases A2 which is activated by Ca2+ influx in the postsynapse. Spermine was 
separated into one class and is controlled by ornithine decarboxylase, whose activity is 
increased by Ca2+ influx. GABA and pyroglutamate, whose synthesis and metabolism 
are all closely related with glutamate, are grouped into one class. Another class 
includes cholesterol and ceramide, which are important component of lipid rafts, are 
grouped for discussion. Dipeptides are not previously reported to be involved in LTP, 
and some possible explanations of the changes are proposed. 
 
Chemical changes 
Creatine (Cr) is an important intracellular high-energy phosphate shuttle synthesized in 
the liver and the kidneys, which is transported to the brain to be stored in phosphate 
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form. When energy is needed for cellular activity, creatine phosphate (PCr) is 
dissociated into free Cr and phosphate for the regeneration of ATP through the 
Cr/PCr/creatine kinase pathway. In the meantime, creatinine as the breakdown product 
of Cr and PCr usually implies the total concentration of Cr and PCr.  
 
Cr increased significantly in most of cell layers of the CA1 and especially in the so and 
sp layers (Fig. 4.3). Meanwhile, creatinine as the breakdown product of Cr and  
PCr decreased significantly in most of cell layers in the CA2. The increase of Cr may 
be the result of high energy demand of the postsynapses of Schaffer collateral-CA1 
during LTP [29]. Since Cr has no significant changes in the CA2/3 regions, the 
decrease of creatinine in the CA2 may be caused by the decrease of PCr if the pH and 
temperature environment of the tissue did not change during LTP induction [30]. The 
decrease of PCr from the CA2 region may be explained by energy demands in 
presynaptic regions which dissociate PCr into Cr, but Cr level might be kept stable by 
the release from presynapse as a potential neurotransmitter. Previous report suggested 
that Cr can potentially function as a neurotransmitter, supported by data showing that 
Cr can be released from neurons in an action-potential dependent manner, while rat 
brain synaptosomes are able to uptake Cr [31,32]. However, postsynaptic Cr receptor 






Depolarization-dependent Ca2+ influx through voltage-gated Ca2+ channels is the main 
cause of LTP induction. It has been demonstrated that direct Ca2+ entrance through 
voltage-dependent calcium channels activate phospholipase A2 (PLA2) to result in 
fatty acids release via phospholipid hydrolysis [6] (Fig. 4.5). Thus, Specific lipid 
messengers are cleaved from these reservoir phospholipids by phospholipases upon 
stimulation by neurotransmitters. It was reported that one such reservoir is the 
phospholipids that typically contain an alkyl-acyl chain in the C1 position and either 
arachidonate (20:4) or docosahexaenoate (22:6) in the C2 position of the glycerol 
backbone. The major PLA2 activated are cytoplasmic PLA2 which results in the 
release of arachidonic acid (AA), docosahexaenoic acid (DHA), and lyso-platelet-
activating factor (PAF). Another PLA2 is secretary PLA2 which is co-released along 
with neurotransmitters, shown to promote active AA remodeling in cultured neurons 
and potentially promote DHA release [6]. 
 
PC containing C20:4 (PC(18:2/20:4)) decreased significantly in the sp layer of CA2 
(Fig. 5.3). This can be the result of PLA2 activation which hydrolyzes PC(18:2/20:4). 
Also, FA(20:4)/(AA) increased in the same location. This is stronger proof that 




Since FA(20:4) and FA(22:6) are all component at the C2 position on the glycerol 
backbone, the increase of them in the CA2/3 should be related to PC hydrolysis via 
PLA2. It was reported that DHA may act as a signaling molecule by binding to 
retinoid X receptor (RXR), a ligand-activated transcription factor, or it may be 
oxygenated to produce messenger molecules such as docosanoid in the postsynapse 
during LTP [6]. Thus, the lack of DHA increase in the CA1 may be due to 
sequestering of the oxygenated form by RXR, which balance the increased formation 
from PC hydrolysis. However, changes in FA(20:4)/AA is different from other fatty 
acids. AA increased significantly in the CA2/3, but decreased significantly in most of 
cell layers of the CA1. In addition to being a product of PLA2 activation modulated by 
Ca2+, AA was also reported to be a retrograde messenger for LTP that diffuses from 
postsynapses to presynapses [33]. Thus, the increase in CA2/3 is not only due to PLA2 
mediated hydrolysis, but also the result of retrograde diffusion. In the postsynapse, AA 
will then be degraded to eicosanoids for intercellular signaling. The decrease of AA in 
the CA1 region can be attributed to its degradation to eicosanoids and diffusion from 
post synaptic region to presynaptic region. 
 
Other fatty acids such as FA(18:1) and FA(22:4) also increased in the CA2/3 regions, 
but they are seldom discussed in the LTP literature. FA(18:1)/oleic acid was reported 
to be released from the 2-acyl position of membrane phospholipids via cleavage by 
calcium-dependent PLA2 [34]. It is known that increase in oleic acid activates protein 
kinase C (PKC), and PKC activation is associated with synapse strengthening [35,36]. 
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FA(22:4) is usually stored in the sn-2 position of phospholipids, and is the metabolic 
product of AA [37]. Thus, increase in FA(22:2) can be the consequence of either or 
both phospholipid hydrolysis via PLA2 or/and the increase of AA.  
 
PE-FA pathway 
Three PEs increased in the CA2/3 regions after LTP (Table 4.1). Among them, two 
20:4 PEs significantly increased in the CA3 region, especially for the slm layer, while 
another PE (PE 38:3) increased largely in the CA2 region. It was reported that 
LPEAT2 is predominantly expressed in the brain, coinciding with the enrichment of 
PE in this tissue, and acts mainly to form Pes by acylating 1-acyl-lyso-PE [38]. It has 
been shown that LPEAT2 activity is not calcium-dependent. However, the increase in 
DHA or AA, which may be substrates of LPEAT2, can potentially be the reasons PEs 
increased after LTP [39]. 
 
Cholesterol and ceramide 
Sphingolipids and cholesterols are major constituents of lipid rafts. Many previous 
works suggested that lipid rafts, especially the cholesterol within, facilitate nerve 
conduction and synaptic exocytosis/endocytosis [40,41]. Ceramides are generated 
when sphingomyelinase (SMase) hydrolyzes sphingophospholipids. Cer(d18:1/18:0) 
increase is observed in most of the cell layers of the CA2 after LTP (Fig. 5.3). Not 
much investigation has been done on the changes of ceramides in relation to LTP and 
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SMase is not directly modulated by Ca2+ influx. However, there are reports showing 
that the PLA2-FA(20:4) pathway mentioned above results in SMase activation [42]. 
Therefore the increase of ceramide after LTP induction might be the consequence of 
cPLA2-FA(20:4) pathway activation. 
 
Cellular cholesterol levels fluctuate in response to strong neuronal activity, with 
implications in excitotoxicity and cellular stress [43]. However, it is not clear how 
changes in cholesterol levels relate to the regulation of synaptic strength during 
plasticity. A recent study demonstrated reduction of cholesterol from intracellular 
membranes of the CA1 pyramidal neurons during LTP induction, and this reduction 
required NMDAR activation [13]. We did not observe significant changes in 
cholesterol levels in the CA1 region, but saw significant increase in the CA2 region 
which contains mostly presynaptic axons (Fig. 4.3). Cholesterol levels detected by 
MSI are total tissue levels within target pixel indiscriminate of subcellular 
compartments or cell types. The reported reduction of intracellular cholesterol may be 
compensated by the reciprocal increases in other cellular compartments, and thus 
failed to show up in our analysis. The significant increase of cholesterol in the CA2 







It has previously been shown that tissue levels of putrescine, spermine, spermidine, 
together with ornithine decarboxylase (ODC) activity, are transiently increased in 
excitable tissue by the activation of voltage- or receptor-gated calcium channels 
[44,45]. Thus, the increase of spermine in the CA2 region may be the result of HFS-
induced NMDA receptor activation and subsequent Ca2+ influx (Fig. 4.3). Also, 
spermine has been reported to specifically facilitate LTP formation by potentiating the 
activation of NMDA receptors [46]. Our result of increased endogenous spermine after 
LTP agrees with the results of previous studies. 
 
Dipeptides  
From our previous work on DA-assisted TiO2 LDI methodology, we found that the 
observed dipeptides may be photo-catalyzed fragments of proteins or longer peptides 
[19]. Thus, the significant increases of the two dipeptides may be the consequence of 
increased expression of certain proteins during LTP. However, since dipeptides are too 
small to trace back to the original protein, this result remains inconclusive. 
 
GABA and pyroglutamatic acid  
GABA and pyroglutamatic acid function directly in the neurotransmission process and 
are closely related to glutamate, which is the most abundant excitatory 
neurotransmitter in the vertebrate nervous system.  
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GABA increased significantly in the CA1 after LTP (Fig. 4.3). GABA is synthesized 
from glutamate by glutamate decarboxylase (GAD) with the cofactor pyridoxal 
phosphate [47,48]. Among GADs, GAD65 is only activated when GABA 
neurotransmission occurs, and is therefore regulated by the synaptic environment. 
GAD65 is activated by phosphorylation via PKC, which is in turn activated by 
increases in the concentrations of DAGs [3], AA, oleic acid [49] and calcium ions 
(Ca2+) [50], all of which increased after LTP (Fig. 4.3). GABA is the major inhibitory 
neurotransmitter whose inhibitory effect is mainly mediated by the GABAA receptor. 
Activation of the GABAA receptor results in the decrease of membrane potential and 
usually induces hyperpolarization. LTP induction is enhanced by blocking GABAA 
receptors [51]. This enhancement is attributed to an increase in postsynaptic Ca2+ 
influx via NMDA receptors [52] since GABAA receptor blockade allows for greater 
postsynaptic depolarization that relieves the voltage-dependent blockade of NMDA 
receptors by Mg2+. In our experiments, Picrotoxin was used as antagonist for GABAA 
receptors [53]. Thus, our detection of GABA increase in presynaptic regions 
demonstrate a decreased release of GABA from presynapses though its synthesis was 
enhanced by Ca2+ influx. 
 
Though pyroglutamic acid itself is not a neurotransmitter, it has close relation with 
glutamate which activates AMPA and NMDA receptors. Pyroglutamic acid is derived 
from glutathione by γ-glutamyl cyclotransferase, which can then form glutamate via 5-
oxoprolinase, which is the only enzyme known to act on pyroglutamic acid [54]. With 
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pyroglutamic acid easily converted into glutamate following hydrolysis, pyroglutamic 
acid can function potentially as a reservoir for glutamate. Pyroglutamic acid increased 
in the CA1 region after LTP, while glutamate levels did not change (Fig. 4.3). One 
possible explanation is that the high glutamate demand for neurotransmission during 
LTP induction largely increased the concentration of glutamate and pyroglutamic acid. 
However, glutamate is released quickly for neurotransmission during LTP, while 
pyroglutamic acid has increased concentration in the cell. The detailed molecular 
mechanism for this regulation is still unclear. 
 
Conclusion 
LTP is a remarkable form of brain plasticity and the best-studied animal model for 
learning and memory. Tracking the chemical changes during LTP is critical for 
unveiling the mechanisms underlying learning and memory as well as finding 
solutions to combat cognitive decline. In this work, we used DA-modified TiO2-
assisted LDI MSI to track the spatio-chemical changes in the hippocampus during LTP 
in the Schaffer collateral-CA1 synapses with focus on lipids and metabolites. From the 
PCA and the OPLS analysis, 20 compounds including amino acids, alkaloids, fatty 
acids, ceramides, diglycerides and phospholipids are identified to dominate the 
chemical changes in the hippocampus after LTP induction. The specific changes and 
spatial distributions of most of these compounds agreed with previous reports. This is 
the first time MSI is utilized to simultaneously visualize the reported signaling 
chemical changes, including the creatinine/Cr change related to energy shuttle, fatty 
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acids/PC/PE changes related to PUFA signaling, GABA change related to 
neurotransmission, spermine change related to NMDA receptor activation, and 
ceramides and cholesterol changes related to lipid rafts. Also, some changes such as 
cholesterol and pyroglutamic acid cannot be explained or are never reported according 
to known pathways. These results provided important new information for molecular 









4.6 FIGURES AND TABLE 
 
Figure 4.1. Illustrated overview of experimental scheme. (A) Schematic of mouse 
hippocampal region divisions for MSI analysis and electrode locations. (B) 
Mean %fEPSP slope to baseline (mean ± s.e.m.) versus time for mice hippocampal 
slices. High frequency stimulation HFS (3 x 100 Hz at test-pulse strength, 1000 ms 
duration, 15 s interval) is given at 10 min (n=5). Inset: sample fEPSP traces of baseline 
in black vs post-high frequency stimulation in red. HFS: high frequency stimulation. 










Figure 4.2. PCA and S-plot of individual cell layers before and after LTP. (A) 
PCA score plots of individual regions before and after LTP induction. (B) S-plot of 
representative cell layers of CA1, CA2 and CA3 by OPLS analysis. Compounds with 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.4. Hierarchical clustering of compounds and their region specific 
relative intensity heatmaps after LTP. (A) Hierarchical clustering of detected 
compounds. Each color indicates biologically closely related species. (B) Heat map of 








Figure 4.5. The reported mechanisms of LTP induced compound changes 
observed in MSI and their direction of change. Simplified mechanism of LTP 
formation is summarized in the illustration. Green arrows indicate decrease while red 
arrows indicate increase. Solid black arrows indicate activation of the enzymes via 
Ca2+ influx, and dashed black arrows indicate activation of the enzymes by increases in 
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CHAPTER FIVE: METABOLOMIC AND LIPIDOMIC CHANGES 
IN THE HIPPOCAMPUS OF DIETARY MODIFIED AGED MICE 
BEFORE AND AFTER LONG TERM POTENTIATION, 
REVEALED BY MASS SPECTROMETRY IMAGING1  
5.1 INTRODUCTION 
When the brain ages, it is believed that the composition of the brain changes and the 
connections in the brain become fixed, which eventually lead to neurodegeneration 
and impairment in learning and memory [1]. It has been reported that aging of the 
brain and a number of neurodegenerative diseases are correlated to neuro-
inflammation [2], neuronal apoptosis [3], breakdown of the blood–brain barrier (BBB) 
[4], decrease in cell membrane fluidity and increase in oxidative stress [5]. Dietary 
intervention is widely studied as a potential method to improve the learning and 
memory of aged animals. For example, diet containing antioxidants was used to 
combat oxidative stress [6] and diet containing key signaling compounds was used to 
control neuro-inflammation [7]. Fish oil, which is rich in n-3 polyunsaturated fatty 
                                                          
1 This work was done in collaboration with Qian Wu Ph.D. from the lab of Prof. Jonathan Sweedler of 
analytical chemistry at the University of Illinois at Urbana-Champaign. This work was supported by the 
Center for Nutrition, Learning and Memory (CNLM) with funding from Abbott’s Nutrition Business. 
Qian Wu assembled the initial manuscript, and James Chu edited the manuscript extensively in 
preparation for submission for publication. James Chu performed the LTP recordings and analyzed the 
electrophysiological data. Qian Wu performed the MSI experiments and analyzed analytical chemistry 
data. Ann Benefiel and Mia Yu Ph.D. provided animal care and managed the diet modifications. 
Jennifer Mitchell Ph.D., Stas Rubakhin Ph.D., Prof. Martha Gillette and Prof. Jonathan Sweedler 
provided guidance for experiments and manuscript assembly.   
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acid (PUFA), is widely studied as an efficient dietary supplement to improve cognitive 
functions [8,9]. However, the mechanisms behind these beneficiary effects of fish oil 
are not well understood. Previous studies suggest it is related to the metabolic products 
of n-3 PUFA, which have anti-inflammatory effects [10]. Recently cocoa powder is 
suggested as another dietary supplement capable of improving cognitive function 
[3,11]. It was observed that flavonoids in cocoa powder function as neuro-protective 
antioxidants, capable of enhancing neuronal function and stimulating regeneration 
possibly via intracellular signaling pathways controlling neuronal survival and 
differentiation. However, the proposed mechanisms remain hypothetical and have not 
been experimentally confirmed. 
 
Mass spectrometry imaging (MSI) is a sensitive and multiplexed approach for the 
characterization and localization of a wide range of small metabolites [12,13], lipids 
[14], peptides, and proteins [15], making it a suitable method for visualizing important 
lipid-related compounds while simultaneously discovering key substrates in signaling 
processes. For example, time-of-flight secondary-ion mass spectrometry (TOF-SIMS) 
had been used to obtain high-resolution images of the microscopic changes in lipid 
composition that occurred at fusion sites between two mating cells of the protozoon 
Tetrahymena thermophile [16]. Indeed, the goal of profiling large-scale changes in 
lipid composition or determining the topographical distributions of individual lipid 
species is no longer beyond reach after MSI techniques are developed. However, it is 
still a less exploited field [17].  
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Recently, we developed a new surface assisted laser desorption/ionization (MALDI) 
MSI method with dopamine (DA)-modified TiO2 monolith. With this method, small 
amino acids, alkaloids, fatty acids together with larger lipids including diglycerides, 
ceramides, phosphoethanolamine (PE) and phosphatidylcholine (PC) can be localized 
simultaneously in brain tissue at 20 µm spatial resolution [18]. In this work, our 
improved MSI method was used to track the lipidomic and metabolomic changes 
induced by diet modifications and determine the most important signaling molecules 
dominating the changes among the compounds. To unveil more information on the 
effects of fish oil (FO) and/or cocoa powder (CP), we tracked the changes in the 
compounds of interest induced by different diet modifications in aged mice. We 
examined Schaffer collateral CA3 – CA1 hippocampal long term potentiation (LTP) in 
these diet modified aged mice. Finally, we investigated how the same compounds 
changed in the diet modified aged animals before and after LTP induction.  
 
5.2 MATERIALS AND METHODS 
Chemicals and Materials 
The following chemicals were purchased from Sigma-Aldrich (St. Louis, MO): n-
methyl-D-glucamine, potassium chloride, sodium phosphate monobasic, (+)-sodium 
L-ascorbate, thiourea, sodium pyruvate, magnesium sulfate anhydrous, picrotoxin, 
titanium(IV) n-butoxide, dopamine hydrochloride (>98%). Concentrated phosphoric 
acid (analytical grade), sodium bicarbonate, HEPES, calcium chloride, D-glucose, 
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sodium chloride, acetonitrile, ethanol, and water (liquid chromatography (LC)/MS 
grade) were purchased from Fisher Scientific (Pittsburgh, PA). 
 
Animal Experiments 
Inbred C57BL/6 mice of both genders between the ages of 20 - 24 months were used. 
Animals were housed under a 12h:12h light-dark cycle at 18–26 °C, 30–70% 
humidity. Food and water were accessible ab libitum. All animal-related procedures, 
including euthanasia by cervical dislocation, were performed in compliance with local 
and federal regulations and according to animal use protocols approved by the 
University of Illinois Institutional Animal Care and Use Committee. 
 
Diet Modifications 
Starting at 16 month, aged mice were fed modified diet ab libitum for at least 4 month 
until used for experiment. Mice body weight were monitored weekly with no drastic 
changes or differences between diets. Experiments were performed without knowledge 
of specific modified diet. The composition of the modified diet is listed in Table 5.1.   
 
Mouse of the correct age was cervically dislocated, decapitated and the brain quickly 
extracted. The brain was chilled in NMDG-artificial cerebral spinal fluid (ACSF) 
slicing solution at 4 °C containing (in mM) NMDG 93, KCl 2.5, NAH2PO4, 1.2, 
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NaHCO3 30, HEPES 20, glucose 25, sodium ascorbate 5, thiourea 2, sodium pyruvate 
3, MgSO4 10 and CaCl2 0.5, bubbled continuously with 95% O2/ 5% CO2. Coronal 
hippocampal slices, 400 µm thick, were obtained with a Leica vibratome.  
 
LTP Induction 
The brain slices were allowed to recover for 10 min in NMDG-ACSF at 30 °C, then 
transferred to a submerged chamber perfused with ACSF solution 2 ml/min containing 
(in mM) NaCl 124, KCl 2.5, NaH2PO4 1.2, NaHCO3 24, HEPES 5, glucose 12.5, 
MgSO4 2, CaCl2 2 and Picrotoxin 50, bubbled continuously with 95% O2/ 5% CO2 at 
30 °C and recover for 1 h before LTP recording. At this point, half of the brain slices 
were placed on glass slides covered with Parafilm and flash frozen over dry ice for 
MSI analysis on the effects of diet modifications on the hippocampus. 
 
Stimulations were performed with a concentric bipolar electrode (FHC) placed at the 
Schaffer collateral between the CA3 and the CA1, recordings were performed with a 
tungsten electrode (FHC) placed at the striatum radiatum at CA1. Field excitatory 
postsynaptic potential (fEPSP) was monitored until stable and input-output curves 
were obtained. Slices were given test-pulses (0.033 Hz) at ~ 40% maximum fEPSP 
throughout the recording. After a minimum of 20 min stable baseline recording, LTP 
was induced by 3 trains of 100 Hz, 1000 ms duration, 15 s interval high frequency 
stimulations (HFS) at test-pulse strength. For signal acquisition, amplifier gain was set 
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to 1000 and filtered between 1 Hz to 3 kHz. Signals were recorded and processed with 
pClamp 10 software. To control for the effect of electrode insertions and electrical 
stimulations on mass spec analysis, control slices were generated from the same brains 
and only subjected to test-pulses without HFS LTP induction.  
 
After LTP recording brain slices were transferred to glass slides covered with Parafilm 
and flash frozen over dry ice for further cryo-sectioning and MSI analysis on the 
effects of LTP induction on the diet modified hippocampus. 
 
Synthesis of TiO2 Monolith and Sample Preparation for MSI  
TiO2 nanoparticles were prepared using the same protocol described in the previous 
chapter. Sample preparation for MSI analysis is described in detail in the previous 
chapter.  
 
Data Processing and Statistical Analysis 
The molecular ion distribution images of tissue sections were visualized using 
flexImaging. Different cell layers in different regions were manually defined according 
to both the optical images and the ion images. The spectra in regions of interest (ROI) 
were exported and imported into ClinProTools (Bruker) with automatic baseline 
subtraction and total ion count normalization. Peaks were selected with a signal/noise 
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threshold greater than 3 on average spectra and matrix-related peaks were removed. 
Selected peaks were exported as m/z value-peak intensity tables. For five repeated 
slides with aged diet mice samples, combat method [19] was used for normalization to 
remove batch effect of different slides using online tool (metaboanalysis 3.0, 
http://www.metaboanalyst.ca/faces/Secure/utils/BatchUpload.xhtml).  
 
After normalization, data from five replicates were combined for multivariate analysis. 
Principal component analysis (PCA)) was performed with OriginPro 8.5 (OriginLab 
Corporation, Northampton, MA), and Orthogonal partial least squares (OPLS) was 
done in SIMCA 14.1.  For comparisons of averaged peak intensities for signals 
acquired from different brain regions in pairs, a two-sample t-test was calculated using 
OriginPro 8.5 in triplicates. For comparison of mean LTP fEPSP magnitudes, 2-way 
ANOVA with Bonferroni’s multiple comparison test was done in GraphPad Prism6.  
 
5.3 RESULTS 
Effect of Diet modification of old mice on LTP and chemical change 
Combinations of cocoa polyphenol and/or fish oil were used as diet supplements for 
aged mice to investigate their effects on hippocampal chemistry and plasticity (Table. 
5.1). The aged mice are fed with different diets from 16-month old for at least 4 
months before the hippocampus was examined with MSI and/or electrophysiology. 
Above established model for investigating spatio-chemical changes analysis with MSI 
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was used to unveil the chemical changes between different diet mice and the difference 
of their chemical changes during synaptic plasticity process.  
 
Chemical difference between aged mice fed with different diets 
PCA was performed on hippocampal slices from the aged mice supplemented with the 
four different diets. It is apparent that the CP + FO diet can be distinguished from the 
other diets in the CA3 region of the PC1 axis, especially when compared to either the 
CP or the FO diet. In the PC3 axis, the FO diet can be distinguished from the CP and 
the CP + FO in most of the cell layers of the CA2 and the CA3 regions. In the CA1 
layers no obvious separations are observed between diets along either the PC1 or the 
PC3 axis. From the loading plots, compounds dominating the changes in the PC1 and 
the PC3 axis are of interest.  
 
From the PCA analysis, the peak area of the compounds of interest in the diet modified 
aged mice were used to construct a hierarchical clustering that categorize the 
compounds into different classes. Five major classes were clustered (Fig. 5.2A). 
Amongst them, small metabolites were divided into three classes; GABA and 
pyroglutamate in one, creatine and creatinine in another, while spermine and PC 36:6 
are each in their own class. All the lipids including the fatty acids, cholesterol, 
ceramides and diglycerides are in one class. The lipids are further categorized into sub 
groups based on their structural differences.  
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The change fold and p-value of all 20 compounds between the diet modified aged 
animals are listed in the supplementary information. Only molecules smaller than 700 
Da had significant differences between the different dietary supplemented groups. 
Representative compounds with significant changes are shown in Figure 5.3.  
 
GABA, pyroglutamate, creatine and creatinine had similar changing trends in different 
diets, with the FO diet having significantly lower levels in the CA1 region compared to 
the CP and the CP + FO diet (Fig. 5.3). In the CA2 and CA3 regions, Cholesterol, 
DAG (34:1), Cer (d36:1) and DHA (FA 22:6) had similar changing trends between 
diets, with the CP + FO diet having the highest levels. The differences between the CP 
diet and the CP + FO diet were significant.  
 
Compared to the control and the FO diet, the CP diet significantly increased the 
GABA content in the CA1 region (Fig 5.2B, 5.3). The FO diet significantly decreased 
creatine level in the aged hippocampus (Fig. 5.3). The CP and the CP + FO diets did 
not change creatine level compared to the control brain. 
 
Cholesterol have been reported to have a moderate loss in brain with age [20]. 
However, other evidences support that there is not an age-dependent change in the 
absolute amount of cholesterol in the hippocampus [21]. It was also shown that 
cholesterol synthesis is decreased in the human hippocampus, while absolute 
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cholesterol content remains stable [22]. These reported results relatively support our 
results that no significant changes of cholesterol have been found between young 
animals and old animals. The CP + FO diet significantly increased the cholesterol 
levels in the CA3 and the CA2 regions compared to the other diets.  
 
Comparison of chemical changes during LTP for four diet samples 
CA3 – CA1 LTP was induced in the hippocampal slices of the diet modified animals. 
MSI was then performed on the slices to measure LTP-induced compound changes 
under different diet modifications. Although not statistically significant, the CP + FO 
diet animal had the highest LTP induction (Fig. 5.4). The FO diet animals meanwhile 
had significantly lower LTP induction compared to the other two diets and the control. 
The CP diet had the most significant compound changes after LTP induction (Fig. 
5.5). The control diet had much less change after LTP, and the FO diet samples had the 
least change. Interestingly, the CP + FO diet had significant decreases in several PEs, 
while the CP diet had significant increases in the same PEs in addition to cholesterol, 




Creatine is an important intracellular high-energy phosphate shuttle synthesized in the 
liver and the kidneys, which is transported to the brain to be stored in phosphate form. 
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When energy is needed for cellular activity, creatine phosphate is dissociated into free 
creatine and phosphate for the regeneration of ATP through the 
Cr/phosphocreatine/creatine kinase (Cr/PCr/CK) pathway. In the meantime, creatinine 
as the breakdown product of creatine and creatine phosphate usually implies the total 
concentration of creatine and creatine phosphate.  
 
It has been shown that aging significantly increases the creatine content in the brain 
[23,24]. However, the FO diet significantly decreased the creatine and creatinine level 
in aged animals (Fig. 5.3). Previous studies showed that creatine can modulate 
GABAergic neurons by acting as partial agonists of the post-synaptic GABAA 
receptor (GABAAR) [25,26]. Moreover, creatine showed neuroprotective effects 
against oxidative stress and prevents neurodegeneration, while creatine 
supplementation can significantly improve LTP [27]. Thus, the lower creatine level in 




It has been demonstrated that direct Ca2+ entrance through voltage-dependent calcium 
channels activate phospholipase A2(PLA2), which releases fatty acids via 
phospholipid hydrolysis [28] (Fig. 5.6). PLA2 cleaves synaptic membrane 
phospholipid reservoirs and releases biologically active lipid messengers. It was 
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reported that one such reservoir is the phospholipids that typically contain an alkyl-
acyl chain in the C1 position and either an arachidonate (20:4) or a docosahexaenoate 
(22:6) in the C2 position of the glycerol backbone. Activation of the cytoplasmic 
PLA2 leads to the release of arachidonic acid (AA or FA 20:4), docosahexaenoic acid 
(DHA or FA 22:6), and lyso-platelet-activating factor (PAF). PLA2 can also be co-
released along with neurotransmitters to promote active AA remodeling in cultured 
neurons and possibly promote DHA release [28]. 
 
DHA and AA are well studied PUFAs which are reported to decrease with age due to 
lipid peroxidation [29]. Age-related decrease of DHA and AA have been linked to a 
decrease in membrane fluidity, which leads to impaired LTP formation. When we 
compared the fatty acids levels between different diets, only DHA was significantly 
higher in the CP + FO diet. Since DHA influences membrane fluidity and is an 
important signaling lipid during LTP formation, its increase in the CP + FO diet may 
be one of reasons for the higher LTP induction (Fig. 5.4). However, it is interesting 
that the FO diet containing high amount of DHA had no significant impact on the of 
DHA content in the hippocampus. This result echoes the reported decrease in n-3 
PUFA levels in aged brains as a consequence of decreased transport of dietary fatty 




Other contributing factors to decreased n-3 PUFAs in the aged brain includes reduced 
dietary intake, undefined impediments to uptake and utilization, or impeded shuttling 
of DHA from the liver to the brain [31]. Increased reactive oxygen species in the 
hippocampus [32,33] also leads to increased lipid peroxidation of the PUFAs [5]. 
Thus, even with elevated intake of DHA with the FO diet, difficulties still exist for the 
DHA to get to the brain. Cocoa polyphenols containing flavonoids on the other hand 
are reported to have anti-inflammatory and antioxidative effects. This perhaps explains 
the ability of the CP + FO diet to significantly increase PUFA contents in the 
hippocampus possibly by decreasing reactive oxygen species. 
 
20:4-DAG 
DAG is an important family of signaling lipids produced from the hydrolysis of 
phosphatidylinositol (PI) and phosphatidylcholine (PC) that can activate downstream 
phosphokinase C (PKC) that contributes to LTP formation [28]. From Figure 5.3, the 
CP + FO diet significantly increased DAG contents in the aged hippocampus, which 
may contribute to the establishment of LTP and possibly explain the higher LTP 
induction compared to other diet modifications (Fig. 5.4). 
 
Cholesterol and ceramide 
Sphingolipids and cholesterols are major constituents of lipid rafts. Many previous 
works suggested that lipid rafts, especially the cholesterol component, facilitates nerve 
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conduction and exocytosis/ endocytosis at the synapse [34,35]. Ceramide is generated 
by the hydrolysis of sphingophospholipids by sphingomyelinase (SMase).  
 
It is now well established that the generation of ceramide through the sphingomyelin 
pathway has functions in signal transduction and the regulations of cell growth, 
differentiation and apoptosis. However, it was also reported that generation of 
ceramide contributes to the loss of mitochondrial membrane integrity, disrupting the 
mitochondrial respiratory chain and stimulate the increase in mitochondria-derived 
reactive oxygen species. When comparing ceramide levels between different diets, the 
CP + FO diet had the highest ceramide level, perhaps contributing to the higher LTP 
induction observed.  
 
Cholesterol levels are regulated in response to strong neuronal activity, linked to 
excitotoxicity and cellular stress. However, it is not clear what the molecular 
mechanisms are that link changes in cholesterol to the regulation of synaptic strength 
during plasticity. Recent research has demonstrated the decrease of cholesterol from 
the intracellular membranes in CA1 neurons during LTP induction by a mechanism 
involving NMDAR activation [36]. 
 
During aging, moderate loss of brain cholesterol by increased expression of 
choleseterol-24-hydroxylase been described [37]. The reduction of cholesterol triggers 
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phospho-Akt accumulation, which in turn perturbs the normal cellular and molecular 
responses induced by long term depression (LTD), such as impaired AMPA receptor 
internalization and its reduced lateral diffusion, and these cause memory impairment 
[38] and poor cognition [39]. The CP + FO diet largely increased the cholesterol level 
in the aged hippocampus, which may contribute to the observed highest LTP induction 
(Fig. 5.4). The FO diet exhibited the lowest LTP induction (Fig. 5.4) and coincidently 
had the lowest hippocampal cholesterol levels. How the combination of CP and FO but 
not FO alone led to higher hippocampal cholesterol requires further investigations. 
 
Spermine 
It has been reported that the tissue levels of putrescine, spermine, spermidine, and the 
activity  of ornithine decarboxylase are transiently increased in excitable tissue by the 
activation of voltage- or receptor-operated calcium channels [40,41]. 
 
It is now presumed that polyamines allosterically regulate the NMDA receptor channel 
complex by acting at a novel binding site distinct from the recognition sites for 
glutamate or glycine. Furthermore, several electrophysiological studies have shown 
that spermine and spermidine potentiate the NMDA induced currents in cultured 
neurons or in Xenopus oocytes transfected to express NMDA receptors. These 
observations are of great interest, implying novel roles of spermine and spermidine as 
neuromodulators in the brain [42]. Also, It has been reported that spermine can 
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facilitate the formation of LTP [42]. This might explain why the CP + FO diet, which 
had the highest spermine levels, had the highest LTP induction (Fig. 5.4). 
Interestingly, spermine was decreased after LTP in the CP + FO diet, suggest 
utilization of the compound in the formation of LTP. 
 
GABA and pyroglutamatic acid  
GABA and pyroglutamatic acid are directly involved in neurotransmission and are 
closely related to glutamate, which is the most abundant excitatory neurotransmitter in 
the vertebrate nervous system. GABA is the major inhibitory neurotransmitter that 
exerts its effects through the GABAA receptor. Activation of the GABAA receptor 
leads to hyperpolarization and the inhibition of neuronal firing. GABAergic neurons 
have GABA as their main output and are the primary inhibitory neurons in the 
vertebrate nervous system. 
 
Not surprisingly, GABA has been shown before to exert an inhibitory effect on the 
induction of long-term potentiation. GABAA receptor antagonist Picrotoxin was used 
in our experiments to negate this inhibitory effect, which appears to be more 
pronounced in aged hippocampus. On the other hand, number of studies reported 
decrease of GABA levels during aging [43], which is linked to age-related memory 
loss [44]. These suggested the importance of GABA in synaptic plasticity. One 
possibility is that the higher GABA levels of the CP + FO diet had positive effects on 
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synaptic plasticity when the inhibitory effect is suppressed. This might explain the 
high LTP induction, while the FO diet with the lowest level of GABA had the lowest 
LTP induction. 
 
Though pyroglutamic acid itself is not a neurotransmitter, it can easily be converted 
into glutamate, which can activate NMDAR and AMPAR. Pyroglutamic acid is 
derived from glutathione through the action of γ-glutamyl cyclotransferase. 
Pyroglutamic acid can be converted into glutamate by 5-Oxoprolinase, the only 
enzyme known to act on pyroglutamic acid (5-oxoproline) [45]. Since pyroglutamic 
acid is easily converted into glutamate with hydrolysis, one of its functions could be a 
reservoir for glutamate. 
 
Pyroglutamic acid level in the hippocampus was reported to decrease with age. In the 
FO diet, pyroglutamic acid level was significantly lower than the other diets. Since 
pyroglutamic acid was reported to improve age-associated memory impairment [46], 
the low pyroglutamic acid level in the FO diet might contribute to the low LTP 
induction (Fig. 5.6). 
 
Conclusion 
Aging leads to deficits in brain plasticity and decline in learning and memory. FO has 
long been studied as an efficient diet supplementation to improve learning and 
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memory. CP is another recently widely studied antioxidant for improving memory and 
learning. In this work, we used DA-modified TiO2-assisted laser desorption/ionization 
(LDI)-mass spectrometry imaging (MSI) to track the spatio-chemical changes in diet 
modified aged hippocampus before and after CA3-CA1 LTP induction. 
 
Aged mice were fed with the FO diet, the CP diet or the combination of both from 16-
month old, and were compared with 24-month aged mice on control diet. LTP results 
showed that aged mice receiving the combination of CP and FO had the highest 
fEPSP, while FO alone gave rise to the lowest fEPSP. Among 20 compounds, the 
levels of around 10 compounds significantly changed between the control diet versus 
the modified diets (n=5). In the energy shuttle pathway, creatine was significantly 
lower in the FO diet mice in CA1 region; in signaling lipid pathways, DHA had 
significantly lower level in FO diet, cholesterol and ceramide have significantly lower 
level in the CP diet. However, the CP + FO diet had significantly higher levels of 
DHA, DAG, cholesterol and ceramide among four aged mice. In the neurotransmitter 
pathways, pyroglutamate have significantly lower level in the FO diet, GABA had 
significantly higher levels in both the CP diet and the CP + FO diet. These results 
show possible underlying mechanisms leading to higher LTP induction in combination 





5.5 FIGURES AND TABLE 
Figure 5.1. Illustrated overview of experimental scheme. Aged mice (20 month of 
age) were given modified diets for 4 months, then subjected to either long term 
potentiation recording or directly for MSI measurements. (A) Microscope image with 
schematic of mouse hippocampal region divisions for MSI analysis and electrode 
placements. (B) Mean %fEPSP slope to baseline (mean ± s.e.m.) versus time for 
different diet modified mouse hippocampal slices. High frequency stimulation (3 x 
100Hz at test-pulse strength, 1000 ms duration, 15 s interval) is given at 10 min (n=6 
per diet). Blue: control, Yellow: fish oil, Green: cocoa powder, Red: cocoa powder + 
fish oil. (C) Example ion map for creatine levels measured with MSI. CP: cocoa 



























Figure 5.2. Hierarchical clustering of the compounds and their region specific 
relative intensity heatmaps in diet modified animals before LTP. (A) Hierarchical 
clustering of detected compounds. Each color indicates biologically closely related 
species. (B) Heat map of corresponding compounds in different regions. C: control, 





Figure 5.3. Ion images and average fold change of compounds in different cell 
layers of diet modified animals before LTP. Each ion image consists of one 
contralateral hippocampus cryosectioned from the freshly prepared slices. (n=5 per 



























Figure 5.4. Long term potentiation results of different diet modified aged mice. 
(A) Mean %fEPSP slope to baseline (mean ± s.e.m.) versus time for old mice with 
different diets after high frequency stimulation (3 x 100 Hz at test-pulse strength, 1000 
ms duration, 15 s interval) at after 10 minutes of stable baseline fEPSP (n=4 for CP, 
CP + FO and FO, and n=5 for Control). Sample fEPSP traces of baseline in black and 
post-HFS in red. (B) 10 minutes binned %fEPSP slope to baseline (individual slices 
and mean ± s.e.m.) versus time for old mice with different diets after high frequency 
stimulation. (2-way ANOVA with Bonferroni’s multiple comparisons test. * p < 0.05, 
** P < 0.01). fEPSP of fish oil diet versus cocoa powder + fish oil diet were 















































































































































































Figure 5.6. Schematic summarized the known functions of the compounds of 
interest and how they changed in different diet modifications. Green arrows 
indicate decrease of compound after diet modification, while red arrows indicate 
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CHAPTER SIX: CONCLUSION & DISCUSSION 
6.1 CONCLUSION & DISCUSSION 
With the advance in mass spectrometry technology, high throughput screens of the 
small peptides in various regions of the central nervous system became achievable [1–
3]. The suprachiasmatic nucleus (SCN), the mammalian center of control for circadian 
rhythm was discovered to contain a rich collection of small peptides [4–6]. One small 
peptide previously unknown to be associated with the SCN is cerebellin-short, a C-
terminus one amino acid truncated form of the 16 amino acid cerebellin peptide highly 
enriched in the cerebellum [7–10]. Originally discovered in 1987, cerebellin peptide 
was speculated to perform important functions in the Purkinje cells [11]. It was later 
discovered that the precursor of cerebellin, Cbln1, is critical for the formation of 
parallel fiber-Purkinje cell synapses in the cerebellum [12,13]. The mechanism of 
Cbln1 function in the cerebellum was reviewed in the first chapter. The study of 
cerebellin peptide on the other hand, remains scarce. Several studies reported that 
synthetic cerebellin peptide can induce the secretion of catecholamine and 
norepinephrine from the adrenal gland in human and rats respectively through indirect 
mechanisms [14,15]. One study reported that intracerebroventricular injection of 
synthetic cerebellin peptide induced feeding behavior in rats possibly by increasing the 
secretion of neuropeptide Y (NPY) from the arcuate nucleus (ARC) [16]. Another 
study reported mechanical hypersensitivity in mice when the synthetic N-terminal one 
amino acid truncated form of cerebellin was intrathecally injected [1]. To the extent of 
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our knowledge no receptor has been identified for the cerebellin peptides, and the 
mechanism of cerebellin functions remain a mystery.  
 
Cbln1 and cerebellin presents the interesting case where both the precursor and the 
processed peptide are biologically functional. In cerebellum, granule cells secret both 
Cbln1 and cerebellin peptides, making the control between precursor vs peptide levels 
and the mechanism of their secretions intriguing questions. Cbln1 contains a signal 
peptide and is likely secreted through the traditional protein export pathway at the 
synapse [17–19]. Cerebellin peptides are known to be present at the synapse and 
undergo Ca2+ and electrical activity mediated secretion [20]. However, signaling 
molecule secretions are not limited to the synapses. Serotonin for example, can be 
secreted from exons and dendrites away from the synapses [21,22]. Arginine 
vasopressin (AVP) and oxytocin in the supraoptic nucleus (SON) are released from 
dendrites through dense core vesicles (DCV) [23]. Cerebellin-short is released from 
the SCN in circadian fashion [4], and we showed that the cleavage product of Cbln1 is 
enriched in the synaptosomes prepared from SCN tissue.  
  
The dramatic difference in size (Cbln1 193 aa vs cerebellin 15 or 16 aa) and the lack of 
functional domains in cerebellin peptides suggest they have different mechanisms of 
action [17]. The idea has been proposed that some peptides produced from functional 
proteins can bind and modulate protein function by either disrupting the multimeric 
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stoichiometry or by covering important binding surfaces [3]. Cerebellin however, was 
shown by yeast two-hybrid assays to have no interaction with Cbln1, an unsurprising 
result due to cerebellin’s lack of the complete C1q domain critical for Cbln1 
multimerization [17]. The C-terminus C1q domain of Cbln1 was also shown to be 
critical for binding to its two known receptors, glutamate receptors delta 1 and 2 
(GluRD1 & GluRD2) [24–26]. The N-terminus of Cbln1 interacts with a subset of 
neurexins, which is also cleaved off in the formation of cerebellin [17,26,27]. It is 
therefore unlikely that cerebellin exerts its function through known Cbln1 binding 
partners. One likely possibility is that cerebellin peptides bind to G protein-coupled 
receptors (GPCRs), since virtually all known neuropeptides exert their effects through 
GPCRs [28]. The SCN expresses a number of orphan GPCRs, and a method for 
systematically screening GPCRs in the SCN was recently described and used to 
discover a new GPCR relevant to circadian regulation [29]. The same method could be 
combined with reporter cell lines expressing candidate GPCRs and screening them for 
activation by the cerebellin peptides. Discerning the receptor for cerebellin peptides in 
the SCN will no doubt be a pivotal step in understanding its mechanism and function 
in circadian time keeping.   
 
Cbln1 in the SCN is under circadian modulation at multiple levels in terms of 
gene/protein expression and peptide processing. 
RT-PCR experiments of CBLN1 in the SCN suggests that the level of CBLN1 mRNA 
changes around the day and peaks at ZT 20. However, the level of the translated 
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product Cbln1 did not vary significantly around the day. Mismatch in the two profiles 
suggests that Cbln1 translation is under circadian modulation. The level of the 15 kDa 
cleavage product in the SCN peaks at ZT 8, which is 12 h after the peak in mRNA. 
After which cerebellin-short release from the SCN peaks later at ZT 16, 4 h after the 
peak in the 15 kDa intermediate. This substantial lag between peak mRNA level and 
peptide release is different from other peptides in the SCN. For instance, AVP and VIP 
mRNA levels in the mouse SCN peak around ZT 9 and ZT 15 respectively, while the 
peptide levels of AVP and VIP peak around 2 h after the mRNA [30,31]. Since Cbln1 
and cerebellin peptides are both biologically active, one possibility is that a portion of 
the Cbln1 produced in the SCN is transported to other regions in the hypothalamus. 
The remaining Cbln1 is then processed into cerebellin-short to be released locally for 
circadian modulation. Fibrous staining of Cbln1 observed immediately dorsal to the 
SCN along the 3rd ventricle supports the hypothesis that Cbln1 is transported either to 
or from the SCN. Alternatively, the 4 h window resolution in sampling the SCN tissue 
did not capture the true peak of Cbln1 protein.  
 
Cbln1 and cerebellin intermediate do not seem to display region specific 
localizations in the SCN 
Unlike well-studied peptides such as AVP, VIP, and GRP among others [30,32,33], 
cerebellin-short did not localize to a distinct region in the SCN. Instead, cerebellin-
short immunoreactivity (IR) co-localized with both AVP and VIP positive cells and 
was generally diffused throughout the SCN. Regional division of the SCN is tied to 
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their functional roles in circadian time keeping. For instance, the ventral VIP and GRP 
regions are responsible for receiving and integrating input signals that can be relayed 
to the dorsomedial AVP region via innervations and peptide secretions [31,34,35]. The 
AVP region then generates and maintains a cohesive rhythm that can be 
communicated to the rest of the brain [36–38]. Being present throughout the SCN 
suggests that cerebellin-short might be secreted from multiple populations of neurons 
and serves to maintain the overall synchrony of the SCN. 
 
On the other hand, the majority of Cbln1 seems to be present outside of the SCN in 
other hypothalamic nuclei. High levels of Cbln1 IR observed in the SON, the PVN and 
the ARC suggest that Cbln1 itself is functional in the hypothalamus. Whether this is 
related to the circadian modulatory function of cerebellin-short in the SCN is 
unknown. It is interesting to note that another member of the C1q family, Cbln2, was 
recently reported to be preferentially expressed in the ventral region of the SCN [39]. 
Cbln2 has high sequence homology to Cbln1 and can cross interact with Cbln1 to form 
heterohexomers that also binds neurexins and GluRD2 [27,40,41]. Previous study 
showed that ectopic expression of Cbln2 in Purkinje cells could rescue the cerebellar 
synaptic deficits of Cbln1-KO mice [40,41]. The possibility that Cbln1 & 2 interact in 




Cerebellin-short peptide can phase-advance the SCN firing rhythm both in the 
day and the early night. Most likely not downstream of the light GLU pathway 
Rhythm of the SCN is manifested in oscillations of multiple measurable cellular 
properties. In addition to the molecular transcription translation feedback loop (TTFL), 
the SCN is rhythmic in spontaneous neuronal activities and membrane potentials 
[42,43]. Ca2+ and redox states of the SCN also undergo daily cycles [44–47]. Rhythms 
in spontaneous firing and membrane potentials are coupled and synchronized 
throughout the SCN, whereas the TTFL and the Ca2+ rhythm are offset in phase across 
the SCN [46]. Cerebellin-short phase advances the SCN spontaneous firing rhythm 
during the day and in the early night. Light and glutamate (GLU) have no effect during 
the day and phase delay the SCN during the early night [48–50]. This suggests that 
cerebellin-short does not function to change the phase of the SCN through the 
GLU/light pathway. Pituitary adenylyl cyclase-activating peptide (PACAP) phase 
advances the SCN during the day by stimulating the cAMP/cAMP-dependent protein 
kinase (PKA) pathway and has no effects in the night [50–52]. On the other hand, 
activation of the cholinergic pathway phase advances the SCN during the night by 
stimulating the cGMP/cGMP-dependent protein kinase (PKG) pathway [53,54].  
 
It is possible that cerebellin-short phase advances the SCN during the day by elevating 
the SCN cAMP level through activating an unidentified G protein-coupled receptor. 
During the early night cerebellin-short might induce phase advance by activating the 
cGMP/PKG pathway. The release of cerebellin-short from the SCN peaked in the early 
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night at ZT 16 [4], so exogenous cerebellin-short administered at CT 14 perhaps 
elicited phase advance by prematurely activating the intended responses for the rise in 
endogenous cerebellin-short level. Interestingly, cerebellin-short did not phase shift the 
SCN during the late night, a time during which the induction of the cGMP will also 
phase advance the SCN [50,54]. Perhaps the activation of cGMP by cerebellin-short in 
the SCN is gated and restricted to the early night window.  
 
What is known so far from past literature and our investigation is summarized in the 
hypothetical bifurcated processing and secretions of Cbln1 versus cerebellin peptides 
in the cerebellum and the SCN (Fig. 6.1). 
 
6.2 REMAINING QUESTIONS AND FUTURE DIRECTIONS 
We showed that cerebellin-short can phase-shift the spontaneous firing rhythm in the 
SCN. Spontaneous firing rhythm of the SCN has been hypothesized to be a 
synchronous output of the SCN. It is related, but not coupled to the TTFL, which is 
responsible for generating and maintaining rhythms in individual SCN cells [46,55]. 
The rhythm in expression of the core clock protein period 2 (Per2) can be monitored 
through bioluminescence imaging of the SCN of the PER2::LUCIFERASE transgenic 
mice [56]. PER2::LUC imaging allows for high throughput monitoring of the dose and 
phase responses in the SCN TTFL at the cellular level [46]. Knowledge on how 
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cerebellin-short influences the TTFL of the SCN could provide insights to its 
mechanism of action and its role in circadian time keeping.  
 
There are more than 14 orphan GPCRs whose function and ligands are unidentified 
[29,57]. A number of these orphan GPCRs were identified to be present in the SCN 
[29], a result not surprising considering the rich collection of peptides expressed by the 
SCN [4,5]. Screening these orphan GPCRs against cerebellin-short can potentially 
identify the receptor and further the understanding of the function and the phase 
shifting mechanism of cerebellin-short.   
 
One method to investigate the physiological effects of cerebellin-short on circadian 
rhythm is to monitor the wheel-running activity of the commercially available Cbln1-
KO mouse. Cbln1 exerts its synaptic formation and maintenance functions in the 
cerebellum through interaction with the glutamate receptor delta 2 (GluRD2). Previous 
study on GluRD2 mutant mice showed that they maintained rhythmic wheel-running 
behavior in D:D despite ataxic phenotype [58]. This suggests that the known Cbln1-
GluRD2 synaptic mechanism is not necessary for maintaining behavior rhythms. If 
Cbln1-KO mice lose rhythmic wheel-running behavior in D:D, it suggest that 
cerebellin-short is important for maintaining rhythm. Alternatively, Cbln1 is important 
for rhythm independent of the Cbln1-GluRD2 mechanism. Rescuing free running 
rhythm via intra-SCN cannulation and injection of cerebellin-short in arrhythmic 
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Cbln1-KO mice would distinguish between these two possibilities. If Cbln1-KO mice 
maintain free running rhythm, then it would suggest that cerebellin-short functions to 
modulate circadian rhythm and is not critical for the maintenance of rhythm.    
Finally, by identifying the endopeptidases responsible for the processing of Cbln1 to 
cerebellin peptides, we would gain insights into how the process is circadianlly 





















Figure 6.1. The hypothetical bifurcated pathways of Cbln1 versus cerebellin 
peptides secretion in the cerebellum and the SCN. (A) In the cerebellum, Cbln1 is 
translated in the granule cells and transported to the parallel fiber-Purkinje cell synapse 
after multimerizing into hexamers. Cbln1 hexamer interacts with presynaptic Nrxnβ 
and postsynaptic GluRD2 to confer synaptic scaffolding function. At the synapse a 
portion of Cbln1 hexamer is internalized by the Purkinje cells or the Bergmann glia 
through the endo-lysosomal pathway and transported to the respected cell soma for 
reasons yet unknown. Somewhere alone this pathway, Cbln1 is also processed through 
multiple steps into the cerebellin peptides. The cerebellin peptides are then secreted to 
perform functions in the cerebellum that are not yet elucidated. (B) In the SCN, Cbln1 
is expressed in neurons and processed through multiple steps into the cerebellin 
peptides. The cerebellin peptides then undergo circadian release to modulate circadian 
function in the SCN through unknown mechanisms. It is unclear whether the full 
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